Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
'Deltacron' - New Variant Found Fusing Omicron And Delta?
>>> Mesoblast Limited (MESO), a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
The company's products under the Phase III clinical trials include -
remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection;
Rexlemestrocel-L to treat advanced chronic heart failure; and
MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing -
MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy.
The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.
Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
<<<
https://finance.yahoo.com/quote/MESO/profile?p=MESO
>>> Single Dose Of Mesoblast's Cell Therapy Shows Durable Reduction In Back Pain
Benzinga
by Vandana Singh
January 12, 2022
https://finance.yahoo.com/news/single-dose-mesoblasts-cell-therapy-114949728.html
Mesoblast Limited (NASDAQ: MESO) announced 36-month follow-up results from the 400-subject Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L in patients with chronic low back pain (CLBP) associated with degenerative disc disease (DDD).
The data showed a durable reduction in back pain lasting at least three years from a single intra-discal injection of rexlemestrocel-L+hyaluronic acid (HA) carrier.
Related: FDA's Office Agrees On 12-Month Reduction In Pain As Primary Endpoint For Mesoblast's Back Pain Study.
Durable reduction in pain was most significant in the pre-specified population with CLBP of shorter duration than the study median of 68 months (n=194).
Pain reduction through 36 months was also seen in the subset of patients using opioids at baseline (n=168). The rexlemestrocel-L+HA group had a substantially greater reduction at all time points than saline controls.
Among patients on opioids at baseline, despite instructions to maintain existing therapies throughout the trial, at 36 months, 28% who received rexlemestrocel-L + HA were not taking an opioid compared with 8% of saline-treated controls.
Price Action: MESO shares traded 2.58% higher at $4.77 premarket on Wednesday.
<<<
>>> Antibody-dependent enhancement
https://en.wikipedia.org/wiki/Antibody-dependent_enhancement
In antibody-dependent enhancement, sub-optimal antibodies (the blue Y-shaped structures in the graphic) bind to both viruses and Fc gamma receptors (labeled Fc?RII) expressed on immune cells promoting infection of these cells.
Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, followed by its replication.[1][2] The suboptimal antibodies can result from natural infection or from vaccination. ADE may cause enhanced respiratory disease and acute lung injury after respiratory virus infection (ERD) with symptoms of monocytic infiltration and an excess of eosinophils in respiratory tract.[3] ADE along with type 2 T helper cell-dependent mechanisms may contribute to a development of the vaccine associated disease enhancement (VADE), which is not limited to respiratory disease.[3] Some vaccine candidates that targeted coronaviruses, RSV virus and Dengue virus elicited VADE, and were terminated from further development or became approved for use only for patients who had those viruses before.
Contents
1 Technical description
2 Coronavirus
2.1 COVID-19
3 Influenza
4 Dengue
5 HIV-1
6 Mechanism
6.1 Different virus serotypes
6.2 Conclusion
7 See also
8 References
Technical description
Antiviral antibodies promote viral infection of target immune cells by exploiting the phagocytic Fc?R or complement pathway.[4] After interaction with the virus the antibody binds Fc receptors (FcR) expressed on certain immune cells or some of the complement proteins. Fc?Rs bind antibodies via their fragment crystallizable region (Fc). Usually the process of phagocytosis is accompanied by virus degradation, however, if the virus is not neutralized (either due to low affinity binding or targeting to a non-neutralizing epitope), antibody binding might result in virus escape and therefore, enhanced infection. Thus, phagocytosis can cause viral replication, with the subsequent death of immune cells. The virus “deceives” the process of phagocytosis of immune cells and uses the host's antibodies as a Trojan horse. ADE may occur because of the non-neutralizing characteristic of the antibody, which binds viral epitopes other than those involved in host-cell attachment and entry. ADE may also happen because the antibodies are present at sub-neutralizing concentrations (yielding occupancies on viral epitopes below the threshold for neutralization).[5][6] In addition ADE can be induced when the strength of antibody-antigen interaction is below a certain threshold.[7][8] This phenomenon might lead to both increased virus infectivity and virulence. The viruses that can cause ADE frequently share some common features such as antigenic diversity, abilities to replicate and to establish persistence in immune cells.[1] ADE can occur during the development of a primary or secondary viral infection, as well as after vaccination with a subsequent virus challenge.[1][9][10] It has been observed mainly with positive-strand RNA viruses. Among them are Flaviviruses such as Dengue virus,[11] Yellow fever virus, Zika virus,[12][13] Coronaviruses, including alpha- and betacoronaviruses,[14] Orthomyxoviruses such as influenza,[15] Retroviruses such as HIV,[16][17][18] and Orthopneumoviruses such as RSV.[19][20][21]
The mechanism that involves phagocytosis of immune complexes via the Fc?RII / CD32 receptor is better understood compared to the complement receptor pathway.[22][23][24] Cells that express this receptor are represented by monocytes, macrophages, some categories of dendritic cells and B-cells. ADE is mainly mediated by IgG antibodies,[23] however, IgM along with complement,[25] and IgA antibodies[17][18] have also been shown to trigger ADE.
Coronavirus
COVID-19
Further information: COVID-19 vaccine misinformation and hesitancy § Antibody-dependent enhancement
ADE was a concern during late clinical stages of vaccine development against COVID-19.[26][27]
<<<
>>> Life insurance deaths up 40% - Dr. Robert Malone’s chilling analysis
The Desert Review
by Justus R. Hope, MD and Robert Malone, MD
Jan 6, 2022
https://www.thedesertreview.com/opinion/columnists/life-insurance-deaths-up-40---dr-robert-malone-s-chilling-analysis/article_d24bccac-6f38-11ec-912f-1f6d8fc5fac4.html
Life Insurance Industry Sounds the Alarm
According to the CEO of OneAmerica, a national life insurance corporation headquartered in Indiana, deaths are up 40% in the third quarter of 2021. These deaths are primarily non-COVID deaths among workers aged 18 through 64.
Scott Davidson sounded the alarm in a business conference call to his industry brethren.
https://odysee.com/@jqrcoad:5/2022-01-04-11-28-21:a
nce-ceo-says-deaths-are-up-40-among-people-ages-18-64/article_71473b12-6b1e-11ec-8641-5b2c06725e2c.html
Dr. Robert Malone, chief architect of the mRNA vaccine technology commented on these findings in a TrialSite News Op-Ed which came from his Substack article. It is republished below.
https://trialsitenews.com/what-if-the-largest-experiment-on-human-beings-in-history-is-a-failure/
What if the largest experiment in human history is a failure?
~ By Dr. Robert Malone
A seasoned stock analyst colleague texted me a link today, and when I clicked it open, I could hardly believe what I was reading. What a headline. “Indiana life insurance CEO says deaths are up 40% among people ages 18-64”. This headline is a nuclear truth bomb masquerading as an insurance agent’s dry manila envelope full of actuarial tables.
People frequently write to Jill and myself. People we have never met. They call, they arrive at the farm by appointment or unannounced, they fill our email in boxes with their inquiries. They all want something; time, attention, an interview. Many want to tell us about their fear, illness, nightmares, or (what often seems like) outright paranoid conspiracies. And then, over time, these fears and “conspiracies” keep getting confirmed. As Jan Jekielek (a senior editor with The Epoch Times) recently said to me, it is getting harder and harder to tell which ones are mere conspiracy theories and which are true reality.
One farm visitor told me of his foreshadowing massive numbers of deaths within three years consequent to the genetic vaccines, and that this was all about the “Great Reset” and the depopulation agenda of the World Economic Forum (WEF). I tried to reassure him that, in my opinion, this was highly unlikely- while privately thinking about how easily people fall into this type of conspiracy ideation, and how I need to be careful to avoid going there when confronting so many public health decisions that appear either incompetent or nefarious.
At the time, I only knew of the WEF as the host of a big annual party in Davos, Switzerland where the uber rich and the hoi oligoi of the Western nations went to watch Ted talks, drink the best wine, see and be seen. Silly me. What a long, strange trip this has been. I doubt that even Hunter S. Thompson could have imagined it in his most drug and booze addled state. Suffice to say, I nominate Ralph Steadman as official illustrator of the SARS-CoV-2 pandemic.
Or a resurrected Hieronymus Bosch.
But I am wandering from a point that I am afraid to clearly state.
It is starting to look to me like the largest experiment on human beings in recorded history has failed. And, if this rather dry report from a senior Indiana life insurance executive holds true, then Reiner Fuellmich’s “Crimes against Humanity” push for convening new Nuremberg trials starts to look a lot less quixotic and a lot more prophetic.
Here is what lit me up in this report from The Center Square contributor Margaret Menge.
“The head of Indianapolis-based insurance company OneAmerica said the death rate is up a stunning 40% from pre-pandemic levels among working-age people.
“We are seeing, right now, the highest death rates we have seen in the history of this business – not just at OneAmerica,” the company’s CEO Scott Davison said during an online news conference this week. “The data is consistent across every player in that business.”
OneAmerica is a $100 billion insurance company that has had its headquarters in Indianapolis since 1877. The company has approximately 2,400 employees and sells life insurance, including group life insurance to employers in the state.
Davison said the increase in deaths represents “huge, huge numbers,” and that’s it’s not elderly people who are dying, but “primarily working-age people 18 to 64” who are the employees of companies that have group life insurance plans through OneAmerica.
“And what we saw just in third quarter, we’re seeing it continue into fourth quarter, is that death rates are up 40% over what they were pre-pandemic,” he said.
“Just to give you an idea of how bad that is, a three-sigma or a one-in-200-year catastrophe would be 10% increase over pre-pandemic,” he said. “So 40% is just unheard of.””
So, what is driving this unprecedented surge in all-cause mortality?
“Most of the claims for deaths being filed are not classified as COVID-19 deaths, Davison said. "What the data is showing to us is that the deaths that are being reported as COVID deaths greatly understate the actual death losses among working-age people from the pandemic. It may not all be COVID on their death certificate, but deaths are up just huge, huge numbers.”
Take a moment to read the entire article. Now. Then let’s continue on, assuming that you have.
AT A MINIMUM, based on my reading, one has to conclude that if this report holds and is confirmed by others in the dry world of life insurance actuaries, we have both a huge human tragedy and a profound public policy failure of the US Government and US HHS system to serve and protect the citizens that pay for this “service.”
IF this holds true, then the genetic vaccines so aggressively promoted have failed, and the clear federal campaign to prevent early treatment with lifesaving drugs has contributed to a massive, avoidable loss of life.
AT WORST, this report implies that the federal workplace vaccine mandates have driven what appear to be a true crime against humanity. Massive loss of life in (presumably) workers that have been forced to accept a toxic vaccine at higher frequency relative to the general population of Indiana.
FURTHERMORE, we have also been living through the most massive, globally coordinated propaganda and censorship campaign in the history of the human race. All major mass media and the social media technology companies have coordinated to stifle and suppress any discussion of the risks of the genetic vaccines AND/OR alternative early treatments.
IF this report holds true, there must be accountability. We are not just talking about running over the first amendment of the Constitution of the United States and grinding it into the mud with an army of artificial intelligence-powered heavy infantry. This article reads like a dry description of an avoidable mass casualty event caused by a mandated experimental medical procedure.
One for which all opportunities for the victims to have become self-informed about the potential risks have been methodically erased from both the internet and public awareness by an international corrupt cabal operating under the flag of the “Trusted News Initiative”. George Orwell must be spinning in his grave.
I hope I am wrong. I fear I am right.
https://trialsitenews.com/what-if-the-largest-experiment-on-human-beings-in-history-is-a-failure/
<<<
$BBBT - Black Bird Biotech announced an independent testing lab, Botanical Research in Motion, Inc. (BRIM), a British Columbia-based botanical research firm, had released the preliminary findings of its four-month long multi-faceted study of its EPA-registered MiteXstreamTM biopesticide. The market is going to be bull soon as this news is spreading!
MiteXstreamTM is available for purchase online at www.mitexstream.com.
Peter Wojcik, CEO/Fellow, Cannabis Researcher, BRIM exclaimed!
"We found conclusive results that MiteXstreamTM is very effective as a stand-alone product and when used as directed”
>>> Why Arena Pharmaceuticals Stock Skyrocketed 80% Today
Motley Fool
By Joe Tenebruso
Dec 13, 2021
https://www.fool.com/investing/2021/12/13/why-arena-pharmaceuticals-stock-skyrocketed-80-tod/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
A healthcare titan wants to acquire the drug developer for nearly $7 billion.
What happened
Shares of Arena Pharmaceuticals ( ARNA 80.38% ) soared 80% on Monday after the drugmaker struck a merger agreement with Pfizer ( PFE 4.58% ).
So what
Arena is a clinical-stage company focused on developing treatments for immuno-inflammatory conditions. It has a promising pipeline of drug candidates in areas such as gastroenterology, dermatology, and cardiology.
Perhaps most promising is Arena's experimental oral therapy etrasimod. Clinical trials are underway to evaluate etrasimod for the treatment of ulcerative colitis, Crohn's disease, and other ailments.
Pfizer is seeking to purchase all of Arena's outstanding stock for $100 per share, or slightly more than double its closing price on Friday. The all-cash deal values Arena at roughly $6.7 billion. The transaction is expected to close in the first half of next year, pending regulatory and shareowner approval.
"Pfizer's capabilities will accelerate our mission to deliver our important medicines to patients," Arena CEO Amit Munshi said in a press release. "We believe this transaction represents the best next step for both patients and shareholders."
Now what
COVID-19 vaccine sales have brought an enormous amount of cash into Pfizer's coffers. The pharmaceutical giant expects to generate as much as $36 billion from its Comirnaty coronavirus vaccine in its 2021 fiscal year.
Pfizer is wisely choosing to use some of this cash to bolster its drug portfolio and long-term growth prospects. That could help to deliver new treatments to patients faster, as well as higher returns to investors.
"Utilizing Pfizer's leading research and global development capabilities, we plan to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases," Pfizer executive Mike Gladstone said.
<<<
ONCT presents at ASH. These results look very good to my untrained eye. Don't know why stock is down. Comments welcome.
GlobeNewswire
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021
Oncternal Therapeutics
Mon, December 13, 2021, 5:00 AM
In this article:
ONCT
-1.09%
Explore the topics mentioned in this article
Updated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) data from the CIRLL study are encouraging, and comparable to previous results presented at ASCO 2021
Objective response rate (ORR) of 81% (21 of 26 evaluable patients) observed for heavily pre-treated patients with MCL treated with zilovertamab plus ibrutinib, which compares favorably to historical ORR of 66% for ibrutinib monotherapy
Complete response (CR) rate of 35% for MCL patients treated with zilovertamab plus ibrutinib (9 of 26 evaluable patients), which compares favorably to historical ORR of 20% for ibrutinib monotherapy, with CRs remaining durable for up to 32 months
Median progression-free survival (PFS) of 35.9 months for MCL patients with median follow-up of 14.4 months, which compares favorably to historical ibrutinib monotherapy PFS of 12.8 months
Median PFS had not been reached for CLL patients with ≤ 2 prior lines of therapy, and median PFS was 36.1 months for patients receiving > 2 prior lines of therapy, with a median follow-up of 29.0 months
Landmark PFS of ~ 85% and ~ 65% at 24 and 36 months, respectively, for CLL patients who had previously received > 2 prior lines of therapy, which compares favorably to historical ibrutinib monotherapy of ~ 65% and ~ 50%, respectively
Landmark PFS of 100% at 36 months for CLL patients who had previously received ≤ 2 prior lines of therapy, which compares favorably to historical ibrutinib monotherapy PFS of ~ 75%
The combination of zilovertamab and ibrutinib continued to be well tolerated, with a safety profile consistent or improved compared with historical data for ibrutinib monotherapy
SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, that will be presented in a poster presentation at the American Society of Hematology (ASH) 2021 Annual Meeting. In the CIRLL study, zilovertamab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with MCL and CLL. The clinical trial is being conducted in collaboration with UC San Diego and is partially funded by the California Institute for Regenerative Medicine (CIRM).
The updated interim data will be presented as a poster presentation at the Mantle Cell, Follicular and Oher Indolent B Cell Lymphomas Clinical and Epidemiological session on December 13, 2021 as part of the ASH 2021 Annual Meeting:
Poster Title: Phase 1/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)
Publication Number: 3534
Session Name: 623, Mantle Cell, Follicular and Oher Indolent B Cell Lymphomas Clinical and Epidemiological
Session Date and Time: December 13, 2021 from 6:00-8:00 pm (Eastern Time)
Location: Georgia World Congress Center, Hall B5
“Our confidence in the differentiation of zilovertamab enabled therapy continues to build as we strengthen our MCL and CLL data set. The median PFS of 35.9 months for heavily pre-treated MCL patients is approximately three times longer than the previously reported median PFS of 12.8 months for ibrutinib monotherapy. The landmark PFS of 85% at 24 months and 65% at 36 months for patients with CLL, regardless of the number of prior lines of therapy, are also encouraging. The combination continues to be generally well tolerated, and we are encouraged by the low grade 3/4 neutropenia rate of 10% for the combination therapy, compared to 29% for ibrutinib alone from its registration study in MCL,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. “We expect to provide an update regarding our dialogue with the U.S. FDA regarding Phase 3 study design later this month.”
The results that will be presented in poster form at ASH 2021 include 31 patients with relapsed/refractory MCL enrolled in the dose-finding and dose-expansion cohorts of the CIRLL clinical trial (Part 1 + Part 2), of whom 26 were evaluable for efficacy as of the October 1, 2021 data cut-off date.
Patients had high-risk factors and were heavily pre-treated at study entry, with 52% having high Ki-67 proliferative index (≥30%) and 45% with intermediate/high sMIPI prognostic score.
The ORR of 81% (21 of 26 evaluable patients), including recently enrolled patients with relatively short follow-up time, is comparable to the 83% ORR (15 of 18 evaluable patients) previously presented at the ASCO 2021 Annual Meeting.
Twelve of 26 (46%) evaluable patients achieved a partial response (PR) and three patients (12%) had stable disease (SD), for a total clinical benefit rate (CR, PR and SD) of 92%.
The complete response rate was 35% (9 of 26 evaluable patients). CRs have remained durable, for up to 32 months as of the data cutoff date.
The ORR and median duration of response were favorable in patients with high-risk features associated with difficult to treat disease:
Ki-67 ≥30%: ORR of 85%; median duration of response of 14 months (95% CI: 13.7, NE), and
>1 prior systemic therapy: ORR of 82%; median duration of response not reached for patients receiving two prior lines of systemic therapy and 34 months (95% CI: 13.8, 34.1) for patients with ≥ 3 prior lines of systemic therapy
Five patients had received prior treatment with ibrutinib, achieving two CRs and two PRs. One patient had SD.
Median PFS was 35.9 months after a median follow-up of 14.4 months (95% CI: 11.4, 19.3), regardless of number of prior systemic therapies. Further, median PFS had not been reached for patients achieving a CR.
Historical data published for single agent ibrutinib for 370 patients with relapsed/refractory MCL from three clinical trials showed an ORR of 66%, CR rate of 20% and median PFS of 12.8 months (Rule et al. 2017, British Journal of Haematology).
As of the October 1, 2021 data cut-off date, 34 patients with CLL have been enrolled in the dose-finding and dose-confirming cohorts of this clinical trial (Part 1 & Part 2), all of which were evaluable for efficacy. Patients had high-risk factors, and most were heavily pre-treated at study entry, with 71% having RAI staging ≥2 and a median of two systemic prior therapies (range 1-15).
The ORR was 91% (31 of 34 evaluable patients), consistent with prior published results.
The CR rate was 6% (2 of 34 evaluable patients), twenty-nine patients (85%) achieved a PR and three patients (9%) had SD, for a total clinical benefit rate (CR, PR and SD) of 100%.
Median PFS in patients with ≤ 2 prior therapies had not been reached, and patients with > 2 prior therapies had a median PFS of ~36.1 months after a median follow up of 29.0 months (95% CI: 27.6, 31.6), in this high risk and mostly heavily pre-treated CLL population.
Based on the Kaplan-Meier curve, landmark PFS of ~ 85% and ~ 65% at 24 and 36 months, respectively, for CLL patients receiving > 2 prior lines of therapy compared favorably to historical ibrutinib monotherapy of ~ 65% and ~ 50%, respectively (Byrd 2019). Landmark PFS was 100% at 36 months for CLL patients with ≤ 2 prior lines of therapy, which compares favorably to historical ibrutinib monotherapy of ~ 75% (Byrd 2019).
Thirty-one patients with CLL have also been enrolled in the randomized efficacy cohort of this clinical trial (Part 3), of which 22 were evaluable for efficacy. Data on this cohort is maturing, and median PFS had not been reached as of the October 1, 2021 cut-off date.
The combination of zilovertamab plus ibrutinib has been well tolerated, with treatment emergent adverse events consistent with those reported for ibrutinib alone. There have been no dose-limiting toxicities and no serious adverse events attributed to zilovertamab alone.
About the CIRLL Clinical Trial
The CIRLL clinical trial (CIRM-0001) is a Phase 1/2 trial evaluating zilovertamab in combination with ibrutinib in separate groups of patients with CLL or MCL. Enrollment of the dose-finding cohorts in CLL and MCL, dose-expansion cohort in CLL and randomized Phase 2 cohort in CLL has been completed. Enrollment of the dose-expansion cohort in MCL is ongoing. Additional information about the CIRM-0001 clinical trial and other clinical trials of zilovertamab may be accessed at ClinicalTrials.gov.
About Zilovertamab (formerly Cirmtuzumab)
Zilovertamab is an investigational, potentially first-in-class monoclonal antibody targeting ROR1, or Receptor tyrosine kinase-like Orphan Receptor 1. Zilovertamab is currently being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of MCL or CLL, in a collaboration with the University of California San Diego (UC San Diego) School of Medicine and the California Institute for Regenerative Medicine (CIRM). In addition, Oncternal is supporting two investigator-sponsored studies being conducted at the UC San Diego School of Medicine: (i) a Phase 1b clinical trial of zilovertamab in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, and (ii) a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL.
ROR1 is a potentially attractive target for cancer therapy because it is an onco-embryonic antigen – not usually expressed on adult cells, and its expression confers a survival and fitness advantage when reactivated and expressed by tumor cells. Researchers at the UC San Diego School of Medicine discovered that targeting a critical epitope on ROR1 was key to specifically targeting ROR1 expressing tumors. This led to the development of zilovertamab, that binds this critical epitope of ROR1, which is highly expressed on many different cancers but not on normal tissues. Preclinical data showed that when zilovertamab bound to ROR1, it blocked Wnt5a signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of the tumor cells. The FDA has granted Orphan Drug Designations to zilovertamab for the treatment of MCL and CLL/small lymphocytic lymphoma. Zilovertamab is in clinical development and has not been approved by the FDA for any indication.
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising, yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes zilovertamab (formerly cirmtuzumab) an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1b/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, as well as a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL. Oncternal is also developing ONCT-808, a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes ONCT-216 (formerly TK216), an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1/2 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. The early-stage pipeline also includes ONCT-534 (formerly GTX-534), a dual-action androgen receptor inhibitor, that is in pre-clinical development as a potential treatment for castration resistant prostate cancer and other androgen-receptor dependent diseases. More information is available at https://oncternal.com/.
Bladerunner
>>> Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022
Yahoo Finance
December 7, 2021
https://finance.yahoo.com/news/innovation-pharmaceuticals-analyzing-full-dataset-123000231.html
WAKEFIELD, MA / ACCESSWIRE / December 7, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provides shareholders with perspectives on the Company's go-forward strategy heading into 2022.
The Company is pleased to report that as of last week it had received all unblinded data/data outputs from the recently completed Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients. The Innovation team is working with biostatistics partners to explore the data-conducting deeper analysis of different subgroups by patient demographics and baseline characteristics, domestic versus overseas COVID-19 standards of care, and more-to potentially identify meaningful patterns and positive trends. Analysis of the compassionate use of Brilacidin in the U.S. in critically-ill COVID-19 patients who had exhausted all other therapeutic options also is planned. Changes to biomarkers and positive clinical changes were observed, with some compassionate use patients administered Brilacidin more frequently and over a longer duration than patients in the Phase 2 Brilacidin COVID-19 trial. Collectively, these actions will help inform next steps for Brilacidin against COVID-19 in the coming year, while Brilacidin's broad-spectrum antiviral properties continue to be researched through NIH and other scientific collaborations.
As discussed previously, the Company remains focused on developing Brilacidin as a novel therapy for Inflammatory Bowel Disease (IBD), specifically Ulcerative Colitis, and also has plans to initiate Phase 3 testing of Brilacidin as an oral rinse treatment for Oral Mucositis (OM) in head and neck cancer patients. Drug product development is ongoing with specialized Contract Development and Manufacturing Organizations (CDMOs) responsible for refining the respective Brilacidin formulation. The IBD and OM clinical indications represent large areas of unmet need, with significant addressable commercial markets.
Elsewhere, Innovation management is engaged in discussions potentially to acquire rights to new pipeline assets, as well as to enter into new licensing agreements. The Company plans to provide updates on these matters as warranted. There is no guarantee, implied or otherwise, that such matters will result in the execution of definitive agreements.
"We were surprised when we learned the topline results of our Phase 2 Brilacidin COVID-19 clinical study. Many factors contributed to our expectations for a successful trial, including compelling in vitro results against SARS-CoV-2, even while we remained pragmatic. Just about all other Pharmas, both large and small, have struggled to show clinical benefit in treating hospitalized COVID-19 patients," commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. "Among critically-ill patients who received Brilacidin under compassionate use in an open label manner, we were told noticeable improvements were seen in key inflammatory biomarkers shortly after receiving Brilacidin treatment. Subsequent positive changes to patient clinical status were also observed. We plan to review these data further, alongside performing subgroup analysis for our Phase 2 COVID-19 trial, as it will help inform our efforts against COVID-19."
Ehrlich added, "The Company is moving ahead with a strategic focus. Efforts are underway to advance Brilacidin's clinical development on multiple fronts, as well as to explore potential new pipeline additions that could be transformational for our company in 2022."
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases.
<<<
JSPR up 15% (was up 30% earlier in the morning) on Citadel Fund (billionaire Ken Griffin) buy of the stock
Jasper Therapeutics (JSPR)
The last Griffin buy is a biotech company. Jasper Therapeutic is a clinical-stage researcher working on hematopoietic stem cell (HSC) therapies. These are the stem cells that give rise to mature human blood cells. Transplants of these stem cells are used to treat both immune system disorders and various cancers.
Jasper has one lead product, JSP191, a novel compound designed to assist and facilitate HSC transplant treatments. The drug candidate is a ‘targeted, humanized monoclonal antibody,’ under development as a clearing and conditioning agent for use prior to HSC transplant. JSP191 causes cell death in immature HSCs, leaving an open space in the bone marrow where transplanted stem cells can engraft and grow. JSP191 is designed to overcome limitations in current conditioning therapy, by acting as a non-toxic clearing agent, and removing one need for more dangerous chemotherapy.
Preclinical studies showed safe use of JSP191 in animal transplant models. The drug candidate is currently in two early stage human clinical trials. A Phase 1b trial for SCID (Severe combined immunodeficiency) is evaluating JSP191 as a sole conditioning agent. SCID is usually only treatable through HSC transplantation. A second trial, also at Phase 1b, is testing JSP191 in a combined therapy with another clearing agent, for use in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Jasper recently reported that the AML/MSD study is enrolling patients in expansion cohorts, and top-line interim data is expected in the first quarter of next year. And this week, the company announced that data on JSP191, showing its long-term benefits as a monotreatment clearing agent in the SCID study, will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting, on December 12.
This is another company that has jumped on the SPAC bandwagon. Jasper merged with Amplitude Healthcare Acquisition Corporation, completing the transaction on September 24 of this year. The combination brought $100 million in gross proceeds to the biopharma, giving the company sufficient capital to operate through the middle of 2023.
Ken Griffin must really like this newly public stock. His firm bought 3,005,035 shares, taking a stake that’s now worth $24.3 million.
Wall Street, like Griffin, sees plenty to appreciate here. Credit Suisse, Judah Frommer writes: “We see promising preliminary safety and efficacy data for JSP191 – a reduced-intensity conditioning regimen for patients undergoing hematopoietic cell transplantation (HCT) – as supportive of a ~$500M peak sales opportunity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), underscored by a broadening addressable patient population. While initial severe combined immunodeficiency (SCID) results are encouraging, SCID’s ultra-orphan status likely limits the commercial opportunity but could de-risk other indications.”
"We see the potential for JSPR to emerge as an attractive M&A candidate if there is further de-risking of the pipeline assets. However, in the near term, we expect interest to be more limited as potential acquirers await clinical data for the various programs," the analyst added.
Frommer’s comments back his Outperform (i.e. Buy) rating, and his $15 price target indicates a potential for 86% share growth in the next 12 months. (To watch Frommer’s track record, click here)
All in all, Jasper shares get a unanimous thumbs up from the analyst consensus, with 4 recent Buy reviews adding up to a Strong Buy rating. The stock is priced at $8.06, while the $18.33 average price target indicates room for an impressive 127% growth on the upside. (See JSPR stock forecast on TipRanks)
Bladerunner
KZIA reports "positive" OS data in GBM. Stock down 15%. Investors were obviously disappointed in the OS numbers.
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
KZIA
-12.90%
Sat, December 4, 2021, 5:00 AM
SYDNEY, Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The results confirm the previously reported safety and efficacy profile with paxalisib in this high unmet need disease.
Key Points
The study recruited 30 patients with newly diagnosed glioblastoma and unmethylated MGMT promotor status, a genetic profile which confers primary resistance to temozolomide, the only existing FDA-approved drug treatment for first line treatment.
60mg once daily was identified as the maximum tolerated dose (MTD) and selected for future studies.
Median overall survival (OS) in the intent-to-treat (ITT) population (n=30) was 15.7 months (11.1 – 19.1), which compares very favourably to 12.7 months historically reported with temozolomide in this patient group.1
Median progression-free survival (PFS) in the ITT population was 8.4 months (6.6 – 10.2), representing a substantial increment over the comparable figure of 5.3 months associated with temozolomide.
In the modified ITT (mITT) population (n=27), which includes only those patients evaluable for efficacy, OS increased to 15.9 months (12.8 – 19.1).
The safety profile of paxalisib was highly consistent with previous clinical studies: hyperglycaemia, oral mucositis, and skin rash were among the most common drug-related toxicities.
Kazia expects to receive a final clinical study report in 1Q CY2022 and intends to seek publication of these data in a peer-reviewed scientific journal thereafter.
Kazia CEO, Dr James Garner, commented, "We are delighted to report positive final data from the completed phase II study of paxalisib. The data continue to demonstrate a clear efficacy signal and favourable safety profile, suggesting a meaningful advantage over temozolomide, the existing standard of care, and validating our decision last year to join the GBM AGILE pivotal study. We have gleaned invaluable insights from this trial, and we are tremendously grateful to the investigators and to the patients who participated. Our task now, as we move rapidly toward a potential marketing authorization, is to confirm and quantify the benefit associated with paxalisib in glioblastoma patients. This indeed is the focus of our participation in GBM AGILE, which commenced recruiting to the paxalisib arm in January 2021. We are increasingly also exploring additional patient populations for which a brain penetrant PI3K/mTOR inhibitor may provide significant advantages over the standard of care."
Professor Patrick Wen, Principal Investigator at Dana Farber Cancer Institute, commented "We are pleased to see the phase II study of paxalisib successfully completed. This data supports the inclusion of paxalisib in the GBM AGILE study, which has recently expanded to Canada. Glioblastoma remains a disease in urgent need of new therapeutic options, and we look forward to seeing further data for paxalisib from GBM AGILE in due course."
Clinical Trial Design
The phase II study of paxalisib was an adaptive trial, conducted in two stages. The first stage sought to determine the most appropriate dose in newly diagnosed patients. The second stage was intended to provide additional information on dosing and to seek a preliminary efficacy signal in order to de-risk transition to a larger, pivotal study.
Consistent with these objectives, the primary objective of the study was to evaluate the safety and tolerability of paxalisib in patients with newly diagnosed glioblastoma. The secondary objectives included typical pharmacokinetic parameters, and efficacy endpoints including overall survival (OS) and progression-free survival (PFS).
The phase II study was conducted in 30 patients at six centres in the United States. It was a single arm study in which all patients received paxalisib as a monotherapy. As such, all data must be interpreted in the context of historical comparators. Specifically, Kazia has referred to the pivotal study of temozolomide, the only existing FDA-approved drug for this patient population. Such comparisons are always inexact, and this study was not designed either to precisely quantify the benefit associated with paxalisib or to demonstrate statistical significance. Rather, these are among the objectives of the ongoing GBM AGILE pivotal trial.
Next Steps
On the basis of earlier interim analyses of this study, Kazia made the decision in 4Q CY2020 to commence participation in the GBM AGILE pivotal study. This global trial recruited its first patient to the paxalisib arm in January 2021 and recruitment is ongoing. Kazia provisionally expects indicative data in CY2023.
Seven other studies of paxalisib are ongoing in other forms of primary brain cancer and in various forms of cancer that has metastasized to the brain. The company is working with investigators to crystalise the timing of initial data read-outs from these studies. Kazia had expected at least two further read-outs by the end of CY2021. Clinicians have now indicated that data early in CY2022 is most likely. The company will continue to keep shareholders closely informed as it receives further feedback from investigators.
Having successfully concluded the phase II study in glioblastoma, the investigators are composing a manuscript for submission and publication to a peer-reviewed academic journal in 2022. Once the data has been more thoroughly analysed, Kazia expects to share further detail with investors as it becomes available.
Bladerunner
>>> Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning
Steven R Gundry
Originally published 8 Nov 2021 Circulation. 2021;144:A10712
Abstract
Our group has been using the PLUS Cardiac Test (GD Biosciences, Inc, Irvine, CA) a clinically validated measurement of multiple protein biomarkers which generates a score predicting the 5 yr risk (percentage chance) of a new Acute Coronary Syndrome (ACS). The score is based on changes from the norm of multiple protein biomarkers including IL-16, a proinflammatory cytokine, soluble Fas, an inducer of apoptosis, and Hepatocyte Growth Factor (HGF)which serves as a marker for chemotaxis of T-cells into epithelium and cardiac tissue, among other markers. Elevation above the norm increases the PULS score, while decreases below the norm lowers the PULS score.The score has been measured every 3-6 months in our patient population for 8 years. Recently, with the advent of the mRNA COVID 19 vaccines (vac) by Moderna and Pfizer, dramatic changes in the PULS score became apparent in most patients. This report summarizes those results. A total of 566 pts, aged 28 to 97, M:F ratio 1:1 seen in a preventive cardiology practice had a new PULS test drawn from 2 to 10 weeks following the 2nd COVID shot and was compared to the previous PULS score drawn 3 to 5 months previously pre- shot. Baseline IL-16 increased from 35=/-20 above the norm to 82 =/- 75 above the norm post-vac; sFas increased from 22+/- 15 above the norm to 46=/-24 above the norm post-vac; HGF increased from 42+/-12 above the norm to 86+/-31 above the norm post-vac. These changes resulted in an increase of the PULS score from 11% 5 yr ACS risk to 25% 5 yr ACS risk. At the time of this report, these changes persist for at least 2.5 months post second dose of vac. We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination.
<<<
https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
$SIGY - Sigyn Therapeutics, A #Biotech #company, Announced that it Successful Completed Research to Address Gram-Positive Bacterial Toxins Associated with #sepsis. This is going to grow the company even bigger.
FULL PR: https://finance.yahoo.com/news/sigyn-therapeutics-reports-successful-completion-123000152.html
SIGT - Sigyn Therapeutics Reported that it Successfully Completed a Study about Gram-Positive Bacterial Toxins Associated with Sepsis, a disease that kills many people every year. Hope this raise the PPE.
FULL PR: https://finance.yahoo.com/news/sigyn-therapeutics-reports-successful-completion-123000152.html
Anti-vaxxer Christian televangelist dies of COVID. He's not the first.
U.S. NEWS
Founder Of Anti-Vaccine Christian TV Network Dies After COVID-19 Fight
Televangelist Marcus Lamb, president and founder of Daystar Television Network, died at age 64.
By
Josephine Harvey
Televangelist Marcus Lamb, the founder of the conservative Christian Daystar Television Network, which repeatedly promoted anti-vaccine messages, died Tuesday after contracting COVID-19. He was 64.
“It’s with a heavy heart we announce that Marcus Lamb, president and founder of Daystar Television Network, went home to be with the Lord this morning,” the network said in a tweet. “The family asks that their privacy be respected as they grieve this difficult loss. Please continue to lift them up in prayer.”
Throughout the coronavirus pandemic, the network has amplified vaccine misinformation, giving routine airtime to vaccine skeptics and anti-vaccination advocates. Some guests have promoted COVID-19 conspiracy theories and treatments that have been widely debunked by medical professionals.
On Tuesday’s broadcast of the daily “Ministry Now” program, his wife, Joni, said that her husband had developed “COVID pneumonia” after contracting the virus. She said he had pre-existing conditions.
“He never talked about that,” she said. “He had diabetes, but he kept it in check. He was very healthy.”
She said they had both been following “many of the protocols talked about here on Daystar” to treat him and that he “100% believed in everything we’ve talked about here on Daystar.”
“There’s no doubt in my mind that this is a spiritual attack from the enemy,” Jonathan Lamb said of his father’s COVID-19 infection during a Nov. 23 broadcast on the network, Religion News Service reported.
“As much as my parents have gone on here to kind of inform everyone about everything going on to the pandemic and some of the ways to treat COVID — there’s no doubt that the enemy is not happy about that. And he’s doing everything he can to take down my dad.”
ADVERTISEMENT
Daystar, headquartered in Texas, is the largest Christian network in the U.S. and the second-largest globally, reaching more than 2 billion people worldwide.
Marcus and his wife hosted their own show, “Marcus and Joni,” which was replaced by their daily “Ministry Now” program during the pandemic.
Daystar broadcast a series of shows featuring prominent vaccine opponents, including Robert Kennedy Jr., Del Bigtree and Dr. Simone Gold, founder of America’s Frontline Doctors, a conservative group that pushed unproven COVID-19 treatments such as hydroxychloroquine. Gold was arrested and charged in connection with the Jan. 6 attack on the U.S. Capitol.
In a December 2020 broadcast, Lamb hosted those three personalities, touting them as “great experts” who could help people make an “informed decision.”
In another broadcast earlier this year featuring Kennedy. and Bigtree, Lamb said the COVID-19 vaccine was “not really a vaccine” and that his guests would be providing “startling up-to-date information that could save your life.”
A number of prominent anti-vaccine Christian media personalities have died of COVID-19 this year. Unvaccinated right-wing radio hosts Dick Farrell, Phil Valentine and Bob Enyart all died after contracting the virus.
Bladerunner
MEIP reports positive results in follicular lymphoma. Stock up 20%. Will apply for "accelerated approval."
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
Tue, November 30, 2021, 4:00 AM
In this article:
MEIP
+20.82%
– Zandelisib Demonstrated 70.3% Objective Response Rate; 35.2% Achieved Complete Response –
– 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event –
– MEI to Host Webcast Today at 8:00am Eastern Time –
SAN DIEGO & TOKYO, November 30, 2021--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate (ORR) as determined by Independent Review Committee (IRC) assessment in the primary efficacy population (n=91). In addition, 35.2% of patients achieved a complete response. The data are currently insufficiently mature to accurately estimate duration of response (DOR). In line with previously reported data from the Phase 1B study, zandelisib was generally well tolerated. With 9.4 months (range: 0.8-24) median duration of follow-up in the total study population (n=121), interim data demonstrated a discontinuation rate due to any drug related adverse event of 9.9%. Patients enrolled in the study will continue to be followed for safety and DOR. Zandelisib is an investigational selective phosphatidylinositol 3-kinase delta ("PI3Kd") inhibitor in clinical development for the treatment of B-cell malignancies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005311/en/
Overview of Preliminary TIDAL Data in Relapsed or Refractory (r/r) FL
The ongoing TIDAL study (NCT03768505) is a global, open-label Phase 2 trial evaluating zandelisib as a single agent across two disease cohorts: the first cohort for the treatment of adults with r/r FL and the second cohort for r/r marginal zone lymphoma (MZL), in both cases after failure of at least two prior systemic therapies, including chemotherapy and an anti-CD20 antibody. Enrollment in the FL cohort is complete; enrollment in the MZL cohort is ongoing. Subject to the results and discussion with the U.S. Food and Drug Administration (FDA), TIDAL study data from each study cohort are intended to be submitted to the FDA to support accelerated approval marketing applications.
The r/r FL cohort enrolled a total of 121 patients, 91 of which were enrolled in the primary efficacy population for the evaluation of ORR and DOR. The median age of patients with FL was 64 years old. Patients enrolled in both the FL primary efficacy and total patient populations received a median of 3 prior lines of treatment (range: 2-8). Patients were administered zandelisib once daily for two 28-day cycles as response induction therapy, followed thereafter by once daily dosing for the first seven days of each subsequent 28-day cycle, a schedule called Intermittent Dosing Therapy (IDT).
Efficacy
The ORR in the 91 patients with r/r FL enrolled in the primary efficacy population was 70.3% (n=64), 95% CI=59.8, 79.5, as assessed by IRC after a minimum follow-up of 6 months; the complete response rate was 35.2%, 95% CI=25.4, 45.9. The ORR represents the primary endpoint of the TIDAL study.
As of the data cutoff date, the data are not sufficiently mature to accurately estimate the final DOR in the FL primary efficacy population, a secondary outcome measure of the TIDAL study. However, with a median follow-up time for response of 8.4 months, the median DOR had not been reached. The data cutoff date is approximately 6 months after the last patient in the primary efficacy population received their first dose of zandelisib.
Safety and Tolerability
Zandelisib appeared generally well-tolerated in the total TIDAL study population through the data cutoff date. The safety observed in TIDAL was consistent with data previously reported from the Phase 1B study (NCT02914938) evaluating zandelisib in patients with B-cell malignancies as a single agent or in combination with rituximab (Rituxan®).
As of the data cutoff date, with a median follow up of 9.4 months (range: 0.8-24) in the total FL study population, the incidence of Grade ≥3 Adverse Events of Special Interest were: 1.7% ALT/AST elevation, 1.7% colitis, 5% diarrhea, 2.5% mucositis, 0.8% pneumonitis, and 3.3% rash. The discontinuation rate due to any drug related adverse event in the group was 9.9%, also as of the data cutoff date.
A more complete report of the TIDAL data as of the data cutoff date will be submitted for presentation at upcoming scientific congresses in 2022.
"The emerging zandelisib data are very promising and indicate the potential to positively impact the standard-of-care for patients with relapsed or refractory follicular lymphoma," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. "The response data and interim safety data reported today support our plans to continue discussions with the FDA on timing of an accelerated approval submission, and we look forward to reporting a more comprehensive review of the data at upcoming medical conferences while continuing this trial and continuing to advance the zandelisib clinical development program in indications beyond follicular and marginal zone lymphomas with our partner, Kyowa Kirin."
"We are encouraged by the zandelisib data reported today from the TIDAL study," said Yoshifumi Torii, PhD, Executive Officer, vice president, Head of R&D Division of Kyowa Kirin. "Our team is continuing to study this investigational medicine with our partner MEI Pharma in the hopes of understanding zandelisib’s value and bringing more hope to lymphoma patients around the world."
MEI Pharma Conference Call and Webcast
MEI will host an investor and analyst webcast event today, November 30, 2021, at 8:00 AM Eastern Time to review the TIDAL phase 2 study data reported today and to provide a corporate overview.
You can access the live webcast with slides under the investor relations section of MEI's website on the "Events and Presentation" page at: www.meipharma.com. A replay of the webcast will be archived for at least 30 days after the conclusion of the live event.
To view additional media and investor resources from MEI Pharma click here.
About Zandelisib
Zandelisib, a selective PI3Kd inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, treatment for patients with B-cell malignancies. Clinical trials are investigating the efficacy and safety of zandelisib utilizing an Intermittent Dosing Regimen (IDT), as a single agent and in combination with other modalities for the treatment of patients with B-cell malignances. The IDT leverages molecular and biologic properties specific to zandelisib.
In March 2020 the FDA granted zandelisib Fast Track designation for treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least 2 prior systemic therapies. In November 2021 the FDA granted zandelisib Orphan Drug designation for the treatment of patients with follicular lymphoma.
In April 2020, MEI and Kyowa Kirin entered a global license, development, and commercialization agreement to further develop and commercialize zandelisib. MEI and Kyowa Kirin will co-develop and co-promote zandelisib in the U.S., with MEI booking all revenue from the U.S. sales. Kyowa Kirin has exclusive commercialization rights outside of the U.S.
Ongoing zandelisib studies include the cohort in TIDAL evaluating patients with r/r marginal zone lymphoma and continuing follow up in the cohort of the study evaluating patients with r/r follicular lymphoma. Also ongoing is the Phase 3 COASTAL study (NCT04745832) comparing zandelisib plus rituximab to standard of care chemotherapy plus rituximab, in patients with r/r follicular or marginal zone lymphomas who received ≥ 1 prior line of therapy, which must have included an anti-CD20 antibody in combination with chemotherapy or lenalidomide. COASTAL is intended to support marketing applications in the U.S. and globally. Pending FDA agreement, COASTAL is also intended to act as the required confirmatory study for potential U.S. accelerated approvals of zandelisib based on the TIDAL study.
Other ongoing studies include a Phase 2 pivotal study in Japan (NCT04533581) in patients with indolent B-cell non-Hodgkin's lymphoma (iNHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and Waldenström's macroglobulinemia (WM) conducted by Kyowa Kirin.
About the TIDAL Phase 2 Study
The TIDAL study (Trials of PI3Kd DeltA in Non-Hodgkin's Lymphoma) is a global Phase 2 trial evaluating zandelisib as a single agent across two study cohorts: the first cohort for the treatment of adults with r/r FL and the second cohort for r/r MZL, in both cases after failure of at least two prior systemic therapies including chemotherapy with an alkylating agent and an anti-CD20 antibody. Subject to the results and discussions with the FDA, data from each study cohort are intended to be submitted to the FDA to support separate accelerated approval marketing applications under 21 CFR Part 314.500, Subpart H.
The study is evaluating zandelisib administered once daily at 60 mg for two 28-day cycles as response induction therapy, followed thereafter by Intermittent Dosing Therapy, or "IDT." The zandelisib IDT consists of once daily dosing for the first seven days of each subsequent 28-day cycle and was developed based on zandelisib-specific preclinical and clinical supporting evidence. The primary efficacy endpoint is the rate of objective responses to therapy and other endpoints will include duration of response and tolerability of zandelisib. The primary efficacy population sample size for r/r FL is 91 patients and the primary efficacy population sample size for r/r MZL is 64 patients. Complete enrollment of the FL primary efficacy population was announced in April 2021. The total study population in the FL cohort is 121 patients to provide additional safety data for the registration application.
More information about this trial is available at ClinicalTrials.gov (NCT03768505).
About PI3K Delta
Phosphatidylinositol 3-kinase delta (PI3Kd) is often overexpressed in cancer cells and plays a key role in the proliferation and survival of hematologic cancers. Targeting the inhibition PI3Kd is a validated strategy in various B cell malignancies, including follicular and marginal zone lymphomas. However, PI3Kd inhibition can lead to immune dysregulation, including inhibition of regulatory T-cell (T-reg) activity, which is understood to contribute to immune-mediated treatment-limiting toxicities.
Strategies to minimize immune dysregulation, while maintaining tumor control with PI3K inhibitors, are required. Subject to suitable pharmacodynamic characteristics, intermittent dosing of PI3Kd inhibitors is a promising approach to decouple the inhibitory activity on malignant B-cells from T-reg inhibition, potentially allowing T-reg recovery, improving tolerability and optimizing the therapeutic potential of this class of therapy.
About Follicular Lymphoma
Follicular lymphoma (FL) is the most common indolent lymphoma, comprising about 20-30% of all non-Hodgkin lymphomas (NHL). The disease also forms on B-cells, is chronic in most cases and tends to progress slowly. Follicular lymphoma is most common in the elderly, having a median age at diagnosis of approximately 65 years old. Sometimes follicular lymphomas can transform into a more aggressive form of large B-cell lymphoma, a fast-growing type of NHL.
About MEI Pharma
MEI Pharma, Inc. (NASDAQ: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S. Food and Drug Administration and other regulatory authorities globally. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit www.meipharma.com. Follow us on Twitter @MEI_Pharma and on LinkedIn.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, the company applies cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com. Follow us on Twitter @KyowaKirin_US and on LinkedIn.
Bladerunner
>>> FDA Slams Kura Oncology With A Clinical Hold — And Investors Slam Its Stock
Investor's Business Daily
ALLISON GATLIN
11/24/2021
The Food and Drug Administration placed Kura Oncology's (KURA) leukemia study on partial hold Wednesday after a patient died — and the biotech stock plummeted.
Kura is testing its drug, dubbed KO-539, in patients with acute myeloid leukemia. Researchers believe the patient's death is tied to differentiation syndrome, a known side effect in acute myeloid leukemia treatment, Kura said in a news release. Potentially fatal, differentiation syndrome can cause fever, low blood pressure, weight gain and breathing complications.
As a result, Kura can't enroll new patients in the study — a bearish point for the biotech stock. But already enrolled patients can continue to receive KO-539. Patients in the study have relapsed or their cancer doesn't respond to other drugs.
On the stock market today, Kura stock tumbled 15.5% to 14.02. That put the biotech stock at its lowest point since May 2020.
Biotech Stock Dives On FDA Hold
Until the partial hold is resolved, Kura is suspending its guidance on testing timelines.
During its third-quarter report this month, Kura said it expected to enroll 12 patients in each group of the study by the end of the first quarter. The company is evaluating low and high doses of KO-539. The biotech stock briefly popped after its earnings report.
Chief Executive Troy Wilson said Kura is now working to ensure physicians are aware of differentiation syndrome and how to treat it.
Overall, the biotech stock has trended down this year. The biotech stock is now well below its 50-day and 200-day moving averages, according to MarketSmith.com.
<<<
>>> Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treated with SYNB1618
Yahoo Finance
November 22, 2021
https://finance.yahoo.com/news/synlogic-presents-data-demonstrating-reductions-004500425.html
Interim data from Phase 2 SynPheny-1 trial featured in late-breaking oral presentation during 14th International Congress of Inborn Errors of Metabolism Meeting
Data demonstrate ability of SYNB1618 to consume phenylalanine from the GI tract
Synlogic also presents two posters with additional data on next-generation Synthetic Biotic SYNB1934
CAMBRIDGE, Mass., Nov. 22, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of interim data from the company's Phase 2 SynPheny-1 clinical trial showing that treatment with the investigational Synthetic BioticTM medicine SYNB1618 resulted in significant reductions in plasma phenylalanine (Phe) levels in patients with phenylketonuria (PKU). Results were presented today by Dr. Jerry Vockley, MD, PhD in a late-breaking oral presentation during the International Congress of Inborn Errors of Metabolism Meeting in Sydney, Australia.
In an interim analysis of eight patients, treatment with SYNB1618 was associated with a 40% reduction in D5-Phe absorption after a meal challenge, a 20% reduction in mean fasting plasma Phe across all subjects, and a >250 µM mean reduction in fasting plasma Phe among responder subjects. Treatment with SYNB1618 was also generally well tolerated, with no serious adverse events and a tolerability profile consistent with results from previous Phase 1 studies.
"PKU remains a devastating disease on multiple dimensions. Despite approved medicines, many people living with PKU remain in significant need of a treatment option that can work for them," said Dr. Vockley, Chief of Medical Genetics at UPMC Children's Hospital of Pittsburgh and lead investigator on the study. "These data provide evidence that SYNB1618 can reduce plasma Phe levels in PKU patients with an oral therapy that works locally in the gastrointestinal tract."
Synlogic also presented data for SYNB1934, the company's next-generation Synthetic Biotic therapy for the treatment of PKU, in poster presentations during the ICIEM meeting. These presentations demonstrated optimization of the Phe-degrading PAL enzyme contained within SYNB1934 and enhanced Phe consumption activity of SYNB1934 relative to SYNB1618 in healthy volunteers. Synlogic has added an additional arm to the ongoing Phase 2 Synpheny-1 trial to include a cohort of PKU patients treated with SYNB1934.
"These strong results from our Phase 2 study of SYNB1618, along with our emerging preclinical and clinical dataset for SYNB1934 demonstrating an approximate doubling in biomarkers of Phe consumption, provide further validation of the potential for Synthetic Biotic therapies to make a meaningful impact on the lives of patients living with PKU," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "We look forward to building on these positive interim findings with additional data from Synpheny-1 including both SYNB1618 and SYNB1934 in the first half of 2022 as we advance our PKU program toward an expected Phase 3 study start."
About Phenylketonuria
Phenylketonuria (PKU) is an inherited metabolic disease that manifests at birth and is marked by an inability to break down Phe, an amino acid commonly found in many foods. Left untreated, high levels of Phe become toxic and can lead to serious neurological and neuropsychological problems affecting the way a person thinks, feels, and acts. Due to the seriousness of these symptoms, infants are screened at birth in many countries to ensure early diagnosis and treatment to reduce the risk of intellectual disability and other complications.
About SYNB1618 and SYNB1934
SYNB1618 and SYNB1934 are orally administered Synthetic BioticTM medicines being developed as potential treatments for phenylketonuria (PKU). They are engineered strains of the microorganism E. coli Nissle that encodes phenylalanine ammonia lyase (PAL), an enzyme that breaks down Phe. They are intended to address the needs of patients of all age groups through the consumption of Phe in the gastrointestinal tract, which has the potential to lower blood Phe levels and enable the consumption of more natural protein in the diet.
About Synlogic
Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including phenylketonuria (PKU), enteric hyperoxaluria, and homocystinuria. The company is also building a portfolio of partner-able assets in immunology.
<<<
>>> Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
BusinessWire
November 22, 2021
https://finance.yahoo.com/news/enanta-pharmaceuticals-reports-financial-results-210100531.html
Presented First Preclinical Data for EDP-235, an Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19; First-in-Human Study Planned for Early 2022
Reported Positive Clinical Data from Two Phase 1b Studies of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic and NUC-Suppressed Chronic HBV Patients; Terminated Clinical Development of EDP-721, an Oral HBV RNA Destabilizer
Announced Decision to Pursue Combination Approaches with Farnesoid X Receptor (FXR) Agonists for Non-Alcoholic Steatohepatitis (NASH) Through an Out-Licensing Strategy
Royalty Revenue for the Quarter was $23.6 Million
WATERTOWN, Mass., November 22, 2021--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2021.
"We ended fiscal 2021 achieving multiple milestones including presenting positive Phase 1b data of EDP-514 in two major HBV patient populations," stated Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. "We were also excited to present the first preclinical data for EDP-235, our oral protease inhibitor specifically designed to target SARS-CoV-2, and we are making meaningful progress with our Phase 2b RSVP study in RSV. Looking ahead, we expect to make significant advancements across our pipeline and are on schedule to select a new clinical development candidate from our RSV L-inhibitor program by year-end and to report initial data from RSVP in the first half of 2022."
Fiscal Fourth Quarter and Year Ended September 30, 2021 Financial Results
Total revenue of $23.6 million for the three months ended September 30, 2021 consisted of royalty revenue derived almost entirely from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET®, which was unchanged from the royalty revenue of $23.6 million for the three months ended September 30, 2020. For the twelve months ended September 30, 2021, total revenue was $97.1 million compared to $122.5 million for the same period in 2020. Royalty revenue for these periods reflect that treated patient volumes remain suppressed compared to pre-COVID levels, as reported by AbbVie.
Research and development expenses were $48.9 million for the three months ended September 30, 2021, compared to $36.7 million for the three months ended September 30, 2020. For the twelve months ended September 30, 2021, research and development expenses were $174.1 million compared to $136.8 million in 2020. The increases in both periods were due to the timing of clinical trials in the company's virology programs.
General and administrative expenses totaled $8.4 million for the three months ended September 30, 2021, compared to $6.7 million for the three months ended September 30, 2020. For the twelve months ended September 30, 2021, general and administrative expenses were $32.5 million compared to $27.4 million in 2020. The increase was due to additional headcount and related compensation expense.
Enanta recorded an income tax benefit of $8.8 million for the three months ended September 30, 2021 compared to an income tax expense of $10.7 million for the same period in 2020. For the twelve months ended September 30, 2021, Enanta recorded an income tax benefit of $28.6 million, compared to income tax expense of $1.1 million for the twelve months ended September 30, 2020. The income tax expense in 2020 was due to a tax valuation allowance charge of $18.3 million recorded against the company’s deferred tax assets in the three months ended September 30, 2020. The income tax benefit in the current period was due to the provision of the CARES Act of 2020, which enables the company to carry back its current year tax loss to offset taxable income in prior years. This provision will not apply to periods ending after September 30, 2021.
Net loss for the three months ended September 30, 2021 was $24.6 million, or a loss of $1.22 per diluted common share, compared to a net loss of $29.3 million, or a loss of $1.46 per diluted common share, for the corresponding period in 2020. For the twelve months ended September 30, 2021, net loss was $79.0 million, or a loss of $3.92 per diluted common share, compared to a net loss of $36.2 million, or loss of $1.81 per diluted common share for corresponding period in 2020.
Enanta’s cash, cash equivalents and marketable securities totaled $352.4 million at September 30, 2021. Enanta expects that its current cash, cash equivalents and short-term and long-term marketable securities, as well as its continuing royalty revenue, will continue to be sufficient to meet the anticipated cash requirements of its existing business and development programs for at least the next two years.
Financial Guidance for Fiscal Year 2022
Research and Development Expense: $150 million to $170 million
General and Administrative Expense: $35 million to $41 million
Pipeline Programs – Recent Events and Near-Term Milestones
Virology
Respiratory Syncytial Virus (RSV): N-Protein Inhibitor EDP-938
Evaluating EDP-938, an N-protein inhibitor, in a broad clinical development program, consisting of three ongoing Phase 2 trials: RSVP, RSVTx and RSVPEDs.
Continued to establish additional trial sites worldwide for RSVP, which is designed to study the effect of EDP-938 on community-acquired RSV infection in an adult population. While RSV, like influenza, was significantly suppressed while there were mitigation measures in place to control COVID-19, more recently there has been evidence of increased RSV activity in various regions of the world, including parts of the United States and Europe. Enanta expects that enrollment in the RSVP study will be complete during the Northern Hemisphere winter season, if there is no further significant increase in COVID-19 or mitigation measures in those regions. Assuming this enrollment occurs, the company expects data in the first half of 2022.
For RSVTx and RSVPEDs, which were initiated more recently, enrollment is expected to require more than one global RSV season, subject to the uncertainties of the continuing pandemic.
COVID-19 (SARS-CoV-2): Protease Inhibitor EDP-235
Presented preclinical data during the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV)–World Health Organization (WHO) Virtual Conference 2021 demonstrating that oral EDP-235 selectively blocked replication of SARS-CoV-2 in multiple cellular models with nanomolar potency. Further, antiviral activity was maintained against multiple SARS-CoV-2 variants. Good distribution to lung cells was observed with optimized pharmacokinetic properties supporting once-daily, oral dosing without ritonavir boosting. Enanta plans to move EDP-235 into the clinic in early 2022.
HBV: Core Inhibitor EDP-514 and HBV RNA Destabilizer EDP-721
Announced positive final data from both Phase 1b studies of EDP-514 in viremic and NUC-suppressed chronic HBV patients. These data demonstrated that the 200 mg, 400 mg, and 800 mg doses were safe and well-tolerated through 28 days of treatment and displayed pharmacokinetics supportive of once-daily dosing. In viremic patients, treatment with EDP-514 resulted in mean HBV DNA reductions of 2.9, 3.3, and 3.5 logs at 28 days for the 200 mg, 400 mg, and 800 mg cohorts, respectively, compared to a 0.2 log reduction in the placebo group.
Terminated development of EDP-721, an oral HBV RNA destabilizer due to adverse safety signals in a Phase 1 healthy volunteer study.
Respiratory Virology Discovery Initiatives: Enanta’s goal in the second half of 2021 is to identify one more clinical development candidate among the two discovery initiatives below:
RSV L-Protein Inhibitor
On schedule to select a clinical candidate with potent nanomolar activity against both RSV-A and RSV-B by year-end.
Human Metapneumovirus (hMPV)
Continuing lead optimization on potent nanomolar hMPV inhibitors.
Non-Alcoholic Steatohepatitis (NASH)
Announced a strategic decision to discontinue internal development of FXR agonists EDP-305 and EDP-297, to prioritize combination approaches for NASH through out-licensing.
Corporate
Announced the election of Yujiro S. Hata to Enanta’s Board of Directors.
Upcoming Events and Presentations
Evercore HealthCONx, November 30 – December 2, 2021
Piper Sandler 33rd Annual Healthcare Conference, November 30 – December 2, 2021
40th Annual JP Morgan Healthcare Conference, January 10 – 13, 2022
Enanta plans to issue its fiscal 2022 first quarter results press release, and hold a conference call regarding those results, on February 8, 2022.
Conference Call and Webcast Information
Enanta will host a conference call and webcast today at 4:30 p.m. ET. To participate in the live conference call, please dial 844-467-7101 in the U.S. or 270-215-9353 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on November 22, 2021, through 11:59 p.m. ET on November 29, 2021 by dialing 855-859-2056 from the U.S. or 404-537-3406 for international callers. The passcode for both the live call and the replay is 1973737. A live audio webcast of the call and replay can be accessed by visiting the "Events and Presentations" section on the "Investors" page of Enanta’s website at www.enanta.com.
About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2 (COVID-19). Enanta is also conducting research in human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of AbbVie’s leading treatment for chronic HCV infection that it sells in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.
<<<
>>> Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program
Yahoo Finance
November 18, 2021
https://finance.yahoo.com/news/enanta-pharmaceuticals-announces-hepatitis-b-210100317.html
Discontinuing Clinical Development of EDP-721, an Oral HBV RNA Destabilizer
Continuing to Focus on Development of EDP-514 in Combination Regimens as a Functional Cure for HBV
WATERTOWN, Mass., November 18, 2021--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced it is discontinuing development of EDP-721, an oral HBV RNA destabilizer, based on emerging safety observations in the single ascending dose part of a Phase 1 study in healthy volunteers.
"Despite the clean preclinical safety profile demonstrated in comprehensive toxicology studies, safety signals were seen in healthy subjects after administration of EDP-721. Patient safety is our top priority, and we have therefore decided to discontinue further development of this compound," said Jay R. Luly Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. "We are committed to developing a functional cure for chronic hepatitis B patients, and remain confident in EDP-514, our HBV core inhibitor, which has demonstrated safe and robust antiviral activity in Phase 1b studies of viremic and NUC-suppressed patients with chronic HBV infection. We believe core inhibitors will be an important component of a successful combination regimen, and we will look to advance our HBV program with additional mechanisms from internal discovery efforts, external opportunities, or both. Importantly, we are grateful to our Principal Investigator and his study team, and the participants in the Phase 1 study for their commitment to HBV research, and to our team for all their efforts in supporting the development and clinical evaluation of EDP-721."
About Hepatitis B Virus
Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. The virus is most commonly transmitted from mother to child during birth and delivery, as well as through contact with blood or other body fluids.1 It is estimated that over 290 million people worldwide have chronic HBV infection.2 Current approaches to treatment include interferon therapy and/or nucleos(t)ide reverse transcriptase inhibitors. Treatment with interferon offers poor cure rates and is accompanied by serious side effects.3 Nucleos(t)ide reverse transcriptase inhibitors can be very effective at suppressing the virus but rarely result in full eradication of the virus from the liver.4
About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2 (COVID-19). Enanta is also conducting research in human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of AbbVie’s leading treatment for chronic HCV infection that it sells in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.
<<<
>>> Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway
Yahoo Finance
November 22, 2021
https://finance.yahoo.com/news/provention-bio-provides-regulatory-teplizumab-123000070.html
RED BANK, N.J., Nov. 22, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on its ongoing efforts to address U.S. Food and Drug Administration (FDA) considerations cited in the Complete Response Letter (CRL) issued to the Company by the FDA on July 2, 2021, pertaining to comparability between the Company's planned teplizumab commercial product and clinical drug product used in historical trials of teplizumab.
On November 18, 2021, the Company had a Type A meeting with the FDA to discuss the population pharmacokinetic (popPK) model to be used for the purpose of planned commercial and clinical drug product comparison. In preliminary meeting comments, the FDA approved the Company proceeding to populate the popPK model with data collected from patients receiving therapeutic doses of teplizumab in a pharmacokinetic/pharmacodynamic (PK/PD) substudy of the ongoing PROTECT Phase 3 trial in newly diagnosed type 1 diabetes (T1D) patients (Commercial Product N~30 patients, Clinical Drug Product N~130 patients).
The Company's preliminary analysis from the popPK model produced the following top-line results:
Geometric mean of the ratio of commercial to clinical drug product [90% Confidence Interval (CI)]
83.2% AUC Infinity [CI: 76.9 – 89.9]
85.3% AUC Day 13 [CI: 78.0 – 93.3]
86.5% CMAX [CI: 83.9 – 89.3]
These results are not final and are subject to ongoing review of both the data and the popPK model by the FDA and the Company.
As anticipated, given teplizumab's target mediated mechanism of clearance, the difference in exposure (AUC Day 13 and 0-infinity) between commercial product and clinical drug product observed in a prior single, fractional low dose PK/PD study in healthy volunteers is greatly reduced when the products are administered and compared in accordance with the higher therapeutic dosing regimen used in T1D patients. Along with previously reported physicochemical and pharmacodynamic data, as well as the immunogenicity and safety profiles, it is the Company's current opinion that, collectively, these preliminary results support comparability of the commercial product and clinical drug product. The FDA, the ultimate decision maker on the matter, is conducting an independent review of the data and may have a different opinion. The Company looks forward to further discussing these results with the FDA to support the FDA's review.
"We are very pleased that we were able to reach agreement with the FDA on progressing the popPK model, which enabled us to generate the comparability results being shared with you today," said Ashleigh Palmer, Co-Founder and CEO of Provention Bio. "We are encouraged by these preliminary results, which we believe are consistent with our understanding of the target mediated clearance mechanism of teplizumab and could potentially explain the differences observed in the previously reported single, fractional low dose PK/PD study in healthy volunteers. We look forward to continuing our discussions with the FDA as they conduct their own review of the data and determining the next steps in the pathway to the Company's goal of ultimately providing teplizumab to T1D patients who are at risk of developing end-stage insulin-dependent disease."
Additionally, at the Type A meeting held on November 18, 2021, the FDA expressed its concurrence with the Company proceeding to schedule a Type B, pre-Biologics License Application (BLA) re-submission meeting.
The Unmet Need in Type 1 Diabetes (T1D):
Over 1.6 million Americans have T1D, an autoimmune disease caused by the destruction of beta cells. Diagnosis of T1D usually occurs in children and young adults, but it can happen at any age after symptoms appear when a person cannot make enough insulin. However, T1D starts in the body long before any symptoms and can be detected through a blood test. The psychological impact of T1D is hard to quantify, but a diagnosis is life-altering, and regular monitoring and maintenance can be extremely stressful. T1D typically takes more than a decade off a person's life, and life expectancy is reduced by 16 years on average for people diagnosed before the age of 10. Insulin therapy and glucose monitoring are currently the standard of care for treating clinical-stage T1D, and are necessary to keep T1D patients alive. The constant monitoring and administration of insulin represents a significant life-long burden for patients. No disease-modifying treatments for T1D are currently available.
About Teplizumab (PRV-031):
Teplizumab is an investigational anti-CD3 monoclonal antibody (mAb) being developed for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. In the pivotal TN-10 Study, a single 14-day course of teplizumab delayed insulin-dependent, clinical-stage disease by a median of at least two years in presymptomatic patients with Stage 2 T1D compared to placebo. The observed adverse events were mechanism-based, transient, and predictable, including lymphopenia, transaminase elevations, rash, and cytokine release events. These results were published in the New England Journal of Medicine and simultaneously presented at the American Diabetes Association meeting in 2019. More than 800 patients have received teplizumab in multiple clinical studies involving more than 1,000 subjects. In previous studies of newly diagnosed patients, teplizumab consistently demonstrated the ability to preserve beta-cell function as shown by C-peptide, a measure of endogenous insulin production. It correspondingly reduced the need for insulin use. Teplizumab has been granted Breakthrough Therapy Designation by the FDA and PRIME designation by the European Medicines Administration. Provention is currently also evaluating teplizumab in patients with newly diagnosed insulin-dependent T1D (the Phase 3 PROTECT study).
About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
<<<
>>> Innovation Pharmaceuticals Provides Brilacidin Program Update
Yahoo Finance
November 18, 2021
https://finance.yahoo.com/news/innovation-pharmaceuticals-provides-brilacidin-program-133000337.html
WAKEFIELD, MA / ACCESSWIRE / November 18, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on clinical development plans for Brilacidin, the Company's defensin-mimetic drug candidate being evaluated in clinical testing for multiple indications.
The Company remains optimistic about Brilacidin even though the Brilacidin Phase 2 COVID-19 clinical trial did not meet its primary endpoint. There is much still to learn from the trial, with full analysis of the data ongoing. Should deeper analysis yield promising data, the plan is to submit Brilacidin for inclusion in government-sponsored COVID-19 clinical trial platforms.
The Company is further encouraged by compassionate use of Brilacidin, which involved the treatment of extremely critically-ill patients who had exhausted all other therapeutic options. Compassionate use cases comprised Brilacidin being administered over a longer duration (up to 10 days) than in the Phase 2 COVID-19 trial (3 and 5 day dosing), with some patients also receiving higher and more frequent dosing (two doses every 24 hours). Patient data is planned to be compiled and evaluated, which may shed additional light on Brilacidin's treatment potential in COVID-19.
More broadly, evaluation of Brilacidin's broad-spectrum antiviral properties continues through collaborations with NIH scientists and academic researchers, and may introduce opportunities to study Brilacidin in neglected tropical diseases. The Company plans to announce new findings as they are reported to us.
The Company also has not lost sight of the fact that, while Brilacidin for COVID-19 moved to the forefront due to the global pandemic, the focus pre-COVID was on developing Brilacidin for Ulcerative Colitis and Oral Mucositis, both areas of large unmet need with substantial commercial opportunities.
New Inflammatory Bowel Disease (IBD) treatments are sought after given IBD's complex pathogenesis and variability in patient response to any one drug. Oral delivery of Brilacidin to the gut is focused on developing an immediate release, multi-particulate capsule formulation in preparation for clinical testing of Brilacidin in Ulcerative Colitis. Research on Brilacidin stability in the GI tract and its interaction with the gut's microbiome also is underway. Oral Mucositis (OM), a painful side-effect of chemoradiation, similarly represents a tremendous unmet need, as there are no approved drugs for prevention of severe OM. The OM competitive landscape has changed significantly, the result of recent later-stage clinical trial failures by Oragenics, Soligenix and Galera. Development of an optimized Brilacidin oral rinse formulation is in progress, with potential to progress to Phase 3 OM testing in 2022.
The Company believes strongly in Brilacidin's treatment potential and its commercial prospects as a novel drug candidate proven to have antibiotic, anti-inflammatory and antiviral properties. We remain committed to the advancement of our pipeline on multiple fronts and will provide additional updates on pre-clinical and clinical developments as they occur.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases.
<<<
Interview with Dr. Robert Malone, Inventor of using "RNA as a drug" and core mRNA and DNA vaccine technologies -
James Kunstler - >>> Who Will Answer?
https://kunstler.com/clusterfuck-nation/who-will-answer/
Why on earth would any American with a functioning brain believe what he /she /they is being told by the public health officialdom, the politicians, or the news media? For two years, they have lied to you about everything relating to the Covid-19 virus, including where it came from, how it was developed, who sponsored its development, how the vaccines happened to come onstage thirty seconds after the disease entered the scene, how well the vaccines worked, how safe the vaccines were, and whether there were other cheap and effective treatments for the disease.
So, here we are with nearly 200-million Americans fully vaccinated (and 230-million with at least one dose), plus 47-million overall officially registered cases of Covid illness (conferring immunity among the survivors), plus X-number people infected with no symptoms, or people who didn’t get tested when sick, or didn’t bother going to see a doctor or report to a hospital, plus X-number of people with natural immunity to Covid for one reason or another (maybe a high number, based on the Diamond Princess cruise ship ratio of a Pareto-type 80 / 20 distribution) — and now, in the fall of 2021, here comes another surge of Covid-19 among both the vaxxed and un-vaxxed.
Did all that vaxxing help? It apparently did nothing to prevent transmission of the disease. The vaxxed were spreading it as effectively as the unvaxxed, and the vaxxed were catching the disease as easily, too, though supposedly suffering not as badly as the unvaxxed (if you choose to believe the official press releases, and why would you believe them?). Then, along came the reports of “adverse reactions” to the vaccines, many of them quite grave — clots, strokes, infarctions, neurological havoc, organ failure. In mid-October this year, the VAERS registry had it at 17,000 deaths and 26,000 permanent disabilities, and the rule-of-thumb was that these represented only 10 percent of the actual number of adverse events because the VAERS website was so badly designed that it crashed half the time any doctor tried to use it… plus the doctors were being silenced and punished for voicing any distrust of the vaccines.
Then why the mad rush to vaccinate all the children in America? There have been next-to-zero covid deaths among children besides a few hundred with grave co-morbidities like cancer or cystic fibrosis — and the hospitals had a cash subsidy incentive from the federal government to list them as dying “with Covid.” Children are far more likely to suffer harm from the vaccines than from the Covid-19 disease. The child vax experiment is only just underway, and there are already enough cases of myocarditis and other disorders to be very concerned. The medical establishment has no idea what the long-term effects on children might be, in particular on their reproductive systems, since the chief active ingredient in the vaccines, the spike protein, has a proclivity for the sexual organs. It happens, too, by the way, that mothers who got vaxxed in early 2021 are just now giving birth to babies with myocarditis and other signature disorders of adverse mRNA vaccine reactions. Keep your eye on that sub-plot of the story.
One wonders: is this child vax campaign an attempt to eliminate the last major control group in the population? (Or just to eliminate a big demographic chunk altogether?) Is it tied in some way to beating the release date for Pfizer’s “Comirnaty” vaccine — which would vacate the Emergency Use Authorization (EUA) that protects the pharma companies from liability? Despite delirious propaganda from the likes of National Public Radio, the bad news is out, and the bad news is that the Covid vaccines for children are bad news. Parents ought to object to any official attempts to coerce them into vaxxing their kids, but will they? I’d guess that the reaction will be ferocious. Stand by on that.
Meanwhile, what would be an intelligent response to Covid-19 at this point? Well, how about letting it burn through the population as expeditiously as possible, along with an aggressive nationwide early treatment program using existing effective drugs such as ivermectin, hydroxychloroquine, fluvoxamine, budesonide, monoclonal antibodies, for starters, along with vitamin D3, quercetin, zinc, selenium, N-acetyl L-cysteine (NAC)? That would minimize fatalities and confer superior natural immunity throughout the whole population.
Of course, one of the whopper lies you’re being told is that this early treatment protocol doesn’t work. Dozens of clinical studies in other countries and direct clinical experience in this country tell the opposite story: the early treatment protocols work remarkably well. The big question, eventually, will be: who might be held responsible in the public health and medical bureaucracies for militating against early treatment? Was it sheer epic incompetence, or something more malevolent?
<<<
>>> Microrobots designed to deliver drugs to diseased cells find inspiration in starfish larva
Medical X Press
Nov 9, 2021
by Rahel Künzler
ETH Zurich
https://medicalxpress.com/news/2021-11-microrobots-drugs-diseased-cells-starfish.html
The new microbot inspired by starfish larva stirs up plastic beads. Credit: Cornel Dillinger/ETH Zurich
Researchers at ETH Zurich have developed a tiny robot that mimics the movement of a starfish larva. It is driven by sound waves and equipped with tiny hairs that direct the fluid around it, just like its natural model. In the future, such microswimmers could deliver drugs to diseased cells with pinpoint accuracy.
Among scientists, there is great interest in tiny machines that are set to revolutionize medicine. These microrobots, often only a fraction of the diameter of a hair, are made to swim through the body to deliver medication to specific areas and perform the smallest surgical procedures.
The designs of these robots are often inspired by natural microorganisms such as bacteria or algae. Now, for the first time, a research group at ETH Zurich has developed a microrobot design inspired by starfish larva, which use ciliary bands on their surface to swim and feed. The ultrasound-activated synthetic system mimics the natural arrangements of starfish ciliary bands and leverages nonlinear acoustics to replicate the larva's motion and manipulation techniques.
Hairs to push liquid away or suck it in
At first glance, the microrobots bear only scant similarity to starfish larva. In its larval stage, a starfish has a lobed body that measures just a few millimeters across. Meanwhile, the microrobot is a rectangle and ten times smaller, only a quarter of a millimeter across. But the two do share one important feature: a series of fine, movable hairs on the surface, called cilia.
A starfish larva is blanketed with hundreds of thousands of these hairs. Arranged in rows, they beat back and forth in a coordinated fashion, creating eddies in the surrounding water. The relative orientation of two rows determines the end result: Inclining two bands of beating cilia toward each other creates a vortex with a thrust effect, propelling the larva. On the other hand, inclining two bands away from each other creates a vortex that draws liquid in, trapping particles on which the larva feeds.
Depending on whether it is swimming or feeding, the starfish larva generates different patterns of vortices.
Artificial swimmers beat faster
These cilia were the key design element for the new microrobot developed by ETH researchers led by Daniel Ahmed, who is a Professor of Acoustic Robotics for life sciences and healthcare. "In the beginning," Ahmed said, "we simply wanted to test whether we could create vortices similar to those of the starfish larva with rows of cilia inclined toward or away from each other.
To this end, the researchers used photolithography to construct a microrobot with appropriately inclined ciliary bands. They then applied ultrasound waves from an external source to make the cilia oscillate. The synthetic versions beat back and forth more than ten thousand times per second—about a thousand times faster than those of a starfish larva. And as with the larva, these beating cilia can be used to generate a vortex with a suction effect at the front and a vortex with a thrust effect at the rear, the combined effect "rocketing" the robot forward.
In their lab, the researchers showed that the microrobots can swim in a straight line through liquid such as water. Adding tiny plastic beads to the water made it possible to visualize the vortices created by the microrobot. The result is astonishing: both starfish larva and microrobots generate virtually identical flow patterns.
Next, the researchers arranged the ciliary bands so that a suction vortex was positioned next to a thrust vortex, imitating the feeding technique used by starfish larva. This arrangement enabled the robots to collect particles and send them out in a predetermined direction
Besides swimming, the new microrobot can collect particles and steer them in a predetermined direction.
Ahmed is convinced that this new type of microrobot will be ready for use in medicine in the foreseeable future. This is because a system that relies only on ultrasound offers decisive advantages: ultrasound waves are already widely used in imaging, penetrate deep inside the body, and pose no health risks.
The fact that this therapy requires only an ultrasound device makes it cheap, he adds, and hence suitable for use in both developed and developing countries.
Ahmed believes one initial field of application could be the treatment of gastric tumors. Uptake of conventional drugs by diffusion is inefficient, but having microrobots transport a drug specifically to the site of a stomach tumor and then deliver it there might make the drug's uptake into tumor cells more efficient and reduce side effects.
Sharper images thanks to contrast agents
But before this vision can be realized, a major challenge remains to be overcome: imaging. Steering the tiny machines to the right place requires that a sharp image be generated in real time. The researchers have plans to make the microrobots more visible by incorporating contrast agents such as those already used in medical imaging with ultrasound.
In addition to medical applications, Ahmed anticipates this starfish-inspired design to have important implications for the manipulation of smallest liquid volumes in research and in industry. Bands of beating cilia could execute tasks such as mixing, pumping and particle trapping.
<<<
>>> Innovation Pharmaceuticals Announces Topline Results from Phase 2 Clinical Trial of Brilacidin for COVID-19
Accesswire
November 11, 2021
https://finance.yahoo.com/news/innovation-pharmaceuticals-announces-topline-results-143000855.html
WAKEFIELD, MA / ACCESSWIRE / November 11, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported topline results from the Company's Phase 2 clinical trial of Brilacidin in hospitalized patients with moderate-to-severe COVID-19. Brilacidin is being developed for treatment of COVID-19 under FDA Fast Track designation.
Brilacidin did not show a difference compared to placebo in reducing Time to Sustained Recovery Through Day 29, the study's primary endpoint based on clinical status. Clinical status endpoints contain a degree of subjectivity that may impact outcomes of COVID-19 trials. Additional analysis of topline and all study endpoints is ongoing.
"Though disappointed with these topline results, treating moderate-to-severe COVID-19 is an exceptionally difficult patient population," said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. "Companies, such as Merck and Regeneron, also did not show clinical benefit in these groups of patients, although both went on to refocus their development efforts in mild-to-moderate COVID-19 and achieve success. Regarding our Brilacidin antiviral program in general, collaborations with NIH scientists and academic researchers to explore Brilacidin's broad-spectrum antiviral activity in different viruses are ongoing. Initial feasibility work to formulate Brilacidin for potential prophylactic use via inhaled delivery, to leverage Brilacidin's unique virucidal and blocking antiviral properties, also is underway. There are many paths to pursue in the antiviral space. We believe Brilacidin holds tremendous promise as a differentiated antiviral drug candidate and plan to continue its development in this area of great opportunity and unmet need."
Topline safety data showed Brilacidin was generally well-tolerated, with frequency of treatment-emergent adverse events similar between study arms. The number of patients who died totaled eight, four each between active and placebo. The overall mortality rate (6.67%) in the trial was approximately one-half of what is typically observed in this patient population.
The randomized, double-blind, placebo-controlled trial (see NCT04784897) evaluated the efficacy and safety of intravenous Brilacidin administered for 3 or 5 days in addition to standard of care. In the trial, 120 patients were treated, with three-fourths receiving 5 days of study drug. Patients were evenly split between male and female, with a majority categorized as experiencing severe COVID-19 at baseline. Most patients were under 65 years old, with an average age of 58.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases.
<<<
CRIS reports 3rd quarter results
Curis Reports Third Quarter 2021 Financial Results and Business Update
Tue, November 9, 2021, 1:01 PM
In this article:
Enrolled first patient in Phase 1 Study of CA-4948 combination therapy in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Presented additional preclinical data for CA-4948 demonstrating potential in additional hematologic malignancies at AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics
Abstract accepted for CI-8993 at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Clinical Data Update Call to be held in January to discuss updated data from ongoing studies, including the Phase 1/2 monotherapy study of CA-4948 in AML/MDS patients with spliceosome or FLT3 mutation
Management to host conference call today at 4:30 p.m. ET
LEXINGTON, Mass., Nov. 9, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter ended September 30, 2021 and provided business updates.
(PRNewsfoto/Curis, Inc.)
(PRNewsfoto/Curis, Inc.)
"During the third quarter of 2021, we continued to advance our clinical trials of CA-4948, our first-in-class, small molecule IRAK4 inhibitor in nine distinct patient populations across AML, MDS and B cell cancers, including the recent initiation of our Phase 1 combination study in AML/MDS. At the AACR-NCI-EORTC Conference in October, we shared exciting preclinical data highlighting potential applications for CA-4948 across different hematologic malignancies, including pCNS lymphoma, an aggressive lymphoma with severe unmet need for patients, further highlighting the potential broad applicability of CA-4948," said James Dentzer, President and Chief Executive Officer of Curis.
"As we look ahead, we plan to provide a clinical data update in January from our ongoing clinical studies, including safety data from our Phase 1 study of CI-8993 and the latest safety and efficacy data from our CA-4948 study in AML/MDS patients with spliceosome or FLT3 mutations."
"In our ongoing monotherapy AML/MDS study, we expect to achieve our enrollment target of having 10-20 total patients with a spliceosome mutation by year-end. We believe data from these patients may provide for an opportunity to explore discussions with the FDA on a registrational path forward in the first half of 2022," concluded Mr. Dentzer.
Third Quarter 2021 and Recent Operational Highlights
Precision oncology, CA-4948 (IRAK4 Inhibitor; Aurigene collaboration):
Enrollment remains on track in nine distinct patient populations across AML, MDS and B cell cancers.
In November 2021, Curis initiated dosing in the combination stage of the Phase 1/2 study of CA-4948 plus azacitidine and CA-4948 plus venetoclax.
In October 2021, Curis announced new preclinical data highlighting the potential of CA-4948 in additional hematologic malignancies in two presentations at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics.
Curis expects to have 10-20 patients in AML/MDS patients with SF3B1 or U2AF1 spliceosome mutation enrolled by year-end 2021.
Immuno-oncology, CI-8993 (anti-VISTA antibody; ImmuNext collaboration):
Enrollment remains on track in the ongoing Phase 1 dose escalation study of CI-8993, Curis's first-in-class monoclonal anti-VISTA antibody for the treatment of R/R solid tumors.
Curis will hold a poster presentation with new preclinical data on CI-8993 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held from November 12-14, 2021.
Title: Preclinical evaluation of anti-VISTA antibody CI-8993 in a syngeneic huVISTA-KI model
Presenting Author: Andrew M. Scott, MD Olivia Newton-John Cancer Research Institute, Tumour Targeting Laboratory, Melbourne, VIC, Australia
Abstract Number: 324
Abstracts were made available Tuesday, November 9, 2021, at 8:00 a.m.
Virtual ePoster presentations will be available Friday, November 12, 2021, at 7:00 a.m.
Upcoming Planned Milestones for 2022
In January, provide a clinical data update on our ongoing studies, including initial safety data from the ongoing Phase 1 monotherapy study of CI-8993 for the treatment of R/R solid tumors and the latest safety and efficacy data from the Phase 1/2 monotherapy study of CA-4948 in AML/MDS patients with spliceosome mutations that result in aberrant splicing of oncogenic IRAK4-L and patients with FLT3 mutations.
In the first half of the year, provide additional data from the ongoing Phase 1/2 monotherapy study of CA-4948 in patients with R/R AML/MDS at a medical meeting.
In the first half of the year, report initial data at a medical meeting from the ongoing Phase 1/2 combination study of CA-4948 plus ibrutinib in patients with B cell cancers.
Third Quarter 2021 Financial Results
For the third quarter of 2021, Curis reported a net loss of $11.1 million or $0.12 per share on both a basic and diluted basis, as compared to a net loss of $6.0 million, or $0.11 per share on both a basic and diluted basis for the same period in 2020. Curis reported a net loss of $31.8 million or $0.35 per share on both a basic and diluted basis, for the nine months ended September 30, 2021, as compared to a net loss of $22.4 million, or $0.52 per share on both a basic and diluted basis, for the same period in 2020.
Revenues for the third quarter of 2021 and 2020 were $3.0 million and $2.7 million, respectively. Revenues for the nine months ended September 30, 2021 were $7.5 million, as compared to $7.8 million for the same period in 2020. Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge®.
Operating expenses for the third quarter of 2021 were $13.1 million, as compared to $7.5 million for the same period in 2020. Operating expenses for the nine months ended September 30, 2021 were $37.0 million, as compared to $26.4 million for the same period in 2020, and comprised the following:
Costs of Royalty Revenues. Costs of royalty revenues, primarily amounts due to third-party university patent licensors in connection with Genentech and Roche's Erivedge net sales, were $0.2 million for the third quarter of 2021, as compared to $0.1 million for the same period in 2020. Cost of royalty revenues for the nine months ended September 30, 2021 were $0.4 million, as compared to $0.4 million for the same period in 2020.
Research and Development Expenses. Research and development expenses were $8.6 million for the third quarter of 2021 as compared to $4.7 million for the same period in 2020. The increase in direct research and development expenses for the quarter is primarily attributable to increased clinical and manufacturing costs for our programs. Additionally, employee related costs increased by $2.3 million, primarily attributable to increased stock compensation and personnel costs as a result of additional headcount. Research and development expenses were $24.1 million for the nine months ended September 30, 2021 as compared to $17.5 million for the same period in 2020.
General and Administrative Expenses. General and administrative expenses were $4.3 million for the third quarter of 2021, as compared to $2.6 million for the same period in 2020. The increase in general administrative expense was driven primarily by higher costs for stock-based compensation, personnel, and professional and consulting services. General and administrative expenses were $12.5 million for the nine months ended September 30, 2021, as compared to $8.6 million for the same period in 2020.
Other Expense, Net. For the third quarter of 2021 and 2020, net other expense was $1.0 million and $1.3 million, respectively. Net other expense primarily consisted of imputed interest expense related to future royalty payments. Net other expense was $2.3 million for the nine months ended September 30, 2021, as compared to $3.8 million for the same period in 2020.
As of September 30, 2021, Curis's cash, cash equivalents and investments totaled $149.8 million, and there were approximately 91.6 million shares of common stock outstanding. Curis expects that its existing cash, cash equivalents and investments should enable it to maintain its planned operations into 2024.
Conference Call Information
Curis management will host a conference call today, November 9, 2021, at 4:30 p.m. ET, to discuss these financial results, as well as provide a corporate update.
To access the live conference call, please dial 1-888-346-6389 from the United States or 1-412-317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1/2 trial in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration.
In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
James Kunstler blog - >>> Medicine Wants to Kill You
https://kunstler.com/clusterfuck-nation/medicine-wants-to-kill-you/
Historians of the future, savoring ‘possum goulash around their campfires, will marvel that modern medicine squandered its authority, its credibility, and its sacred honor in the Covid Panic of the 2020s, when public health officials and doctors in clinical practice colluded to force mass vaccinations while suppressing news of the harms and injuries the vaccines caused — potentially sacrificing millions of citizens like so many experimental fruit flies.
Poster-boy for this epic debacle was Dr. Eric J Rubin, editor of the New England Journal of Medicine who, serving on the CDC’s advisory vaccine committee, actually said, “We’re never gonna learn how safe the vaccine is until we start giving it.” Giving it to children, that is, which the government authorized last week, even while that same CDC issued a safety advisory warning on vaccine-induced myocarditis (inflammation of the heart), especially in boys and young men.
Nota bene: myocarditis is not a condition you necessarily get over because affected heart muscle cannot replace itself; rather the inflammation leads to scarring of heart muscle and a shortened life-span.
Meanwhile, young vaxxed athletes drop dead of heart failure in shocking numbers on high school gridirons, soccer fields, cricket pitches, bike trails, and running tracks around the world, and ordinary civilians develop a bewildering array of post-vax cardiovascular, neurological, and thrombotic disorders of which only a small fraction end up being recorded in the CDC’s Vaccine Adverse Event Reporting System (VAERS). Those numbers now are at least roughly 10,000 deaths and 20,000 permanently disabled. The VAERS website is so kludgy and inadequate that doctors are discouraged from using it — to the degree that only an estimated 10 percent of adverse events are actually reported. Doctors are also threatened with disciplinary punishment for publicizing problems with the vaxxes.
In fact, the news can’t be completely suppressed. It is obvious now — due to the frantic push for “booster” shots — that the various vaccines stop working to prevent infection with Covid-19 after several months. What is only partially understood is the action of the spike proteins that linger in the body post-vax, but the evidence is not good, since they have a particular affinity for attaching to the endothelial linings of blood vessels generally, and in the capillaries of major organs in particular — especially ovaries and testicles, raising the specter of widespread infertility ahead.
On top of that, the vaccines are suspected of breaking down the immune system, leaving the vaxxed vulnerable to opportunistic infection, disabling the genetic mechanism that allows the body to routinely defeat cancer cells, and turning people’s immune systems against them in auto-immune disorders.
How are the doctors and public health officials behaving in the face of all this? Pushing ever more strenuously for the forced vaccination of everybody of all ages, no matter what, and vilifying anyone who militates for respecting informed consent to be vaccinated. The net result is that doctors appear to have violated en masse their Hippocratic oath of ethics which calls on them to first do no harm.
Everything about the virus and its countermeasures — from the murky origins of it in Dr. Anthony Fauci’s official funding of bioweapons research, to the patent trail of conflicted ownerships and interests in the subsequent vaccine developments, to the fierce suppression of news and debate — suggests nefarious motives, or else a mass psychotic panic among the very highly-trained people society must depend on in a crisis.
It’s also getting harder to tell how much of a crisis this actually is or ever really was. There’s no reliable way of knowing how many people really died as a direct result of Covid, or just tested positive for the virus (with a janky PCR test) when they were struggling with one or more serious illnesses (co-morbidities), especially when there were substantial dollar subsidies at stake from the federal government tied to Covid cases. Nor is it possible to determine right now how many deaths attributed to Covid are actually a result of reactions to the vaccines. Most troubling of all, it looks like the rate of deaths from cardiac disorders, thrombosis, and neurological damage in the general population is noticeably exceeding the normal range — as reported officially in the UK, Ireland, and other countries.
It bears repeating that whatever Covid-19 actually is or where it came from, it’s a disease not a whole lot more deadly in the general population than the flu in a bad season; that in the natural course of things, it would have probably only killed mostly the very old and already sick, and that the rest of the population would have soldiered through it and acquired a sturdy natural immunity superior to anything the vaxxes might confer (even in theory).
My own doctor tried to persuade me to get vaxed-up during a routine physical in October. I asked him if he was aware of the thousands of deaths and disabling adverse events reported on the CDC’s VAERS system. He said the numbers were not true and went on to say that he had “one hundred percent confidence in the vaccines.” He’s always appeared to be a smart and capable person. A year or so ago he was enlisted to act as an executive administrator in the health care org he practices in, and now only sees patients two days a week. Perhaps that leaves him no time to follow the news. Or maybe he has no inclination to follow any news except what comes from sources like cable TV channels, which are almost entirely sponsored by the Pharma industry.
The bottom line for me is that he has compromised my faith in his judgment. I wonder how many other people feel that way about their doctors. The medical profession was already in trouble before Covid came on the scene. It had entered into a demonic symbiotic relationship with the insurance industry that amounted to pervasive racketeering. (Just imagine the hospital bills of all those people with adverse vax reactions that the doctors affected to be mystified by, and ran countless, fruitless tests on.)
The good news for now is that a federal court has stayed the “Joe Biden” vax mandates. The government is expected to dispute that decision today (Monday Nov 8). Meanwhile, the rumor of a general strike against vaccine tyranny, set for today through Thursday, is in the air and we’ll have to stand by to see if anything happens. We should also be standing by in the weeks ahead to see how many more people begin to show symptoms of developing serious bodily disorders from the multiple shots they have been suffered to take.
<<<
>>> What’s All The Buzz About Quercetin?
American Thinker
By Brian C. Joondeph, M.D.
Nov 2, 2021
https://www.americanthinker.com/articles/2021/11/whats_all_the_buzz_about_quercetin.html
Quercetin has been in the news lately, particularly as one of many potential therapeutics that might have some benefit in the prevention or treatment of COVID infection. Is there anything to this?
Big media and the medical establishment are quick to pounce on any “unapproved” potential therapeutics that haven’t gone through large prospective randomized clinical trials and don’t have the seal of FDA approval. Even FDA approval is not enough if the medications are being used off-label, as in the case of hydroxychloroquine or ivermectin. Decades ago, both were deemed safe and effective by the FDA and approved for human use, although not for COVID or similar viral infections as COVID didn’t even exist when the FDA approved these medications.
Today there is a peculiar hostility toward these medications, both of which are on the list of the World Health Organization’s essential medicines. A Fox News host told viewers that hydroxychloroquine “will kill you” and the FDA told its Twitter followers that ivermectin is for horses and cows and to stop using it. This must have been shocking news to millions around the world who take these medications, some for many years, in the U.S. prescribed by a physician, and elsewhere in the world readily available over the counter.
I am not advocating for or against these drugs, instead referring interested readers to other sources of information on the science and potential benefits of these medications in our fight against COVID. Quercetin appears to be the third in this line of potential therapeutics, not yet being called horse paste but, if history is a guide, it may soon be maligned as dog and cat medicine, something that can also be said for many drugs taken by humans but also used in animals.
What is quercetin? It’s described as “a pigment” which may lead CNN or Fox News to equate its use to drinking paint. Technically it is a flavonoid, “a group of plant metabolites thought to provide health benefits through cell signaling pathways and antioxidant effects. These molecules are found in a variety of fruits and vegetables.”
These compounds have several health benefits including reducing the risk of heart disease, cancer, and degenerative brain disorders through anti-inflammatory effects as a free radical scavenger. While present in fruits, vegetables, and green tea, it is also available as a non-prescription supplement in capsule or powder form.
Quercetin, like hydroxychloroquine and ivermectin, is a zinc ionophore, facilitating the entry of zinc into cells where it interferes with viral replication, potentially suppressing COVID infection.
Could quercetin be of benefit against COVID, or for that matter, the common cold or the flu? As are always told to “follow the science”, what does science say?
A 2012 paper published in Antiviral Research found that quercetin inhibits rhinovirus (common cold) replication both in vitro and in vivo, meaning in the laboratory and in humans. Another 2016 paper in Viruses noted that quercetin inhibited influenza A (seasonal flu) virus entry into cells. Is quercetin a cure or panacea? Certainly not as we have no cure for these viral infections. But following the science leads to the conclusion that it helps. But what about for COVID?
Following the science, rather than the FDA Twitter feed, suggests that quercetin may be of benefit in COVID. A 2021 paper in the International Journal of General Medicine, a prospective, randomized, controlled clinical trial of 152 early-stage COVID patients, the type of study always demanded by Dr. Anthony Fauci and the medical smart set, concluded, “Quercetin is a safe agent and in combination with standard care, when used in the early stage of viral infection, could aid in improving the early symptoms and help in preventing the severity of COVID-19 disease.”
The same group published in the same journal, also in 2021, a smaller similarly designed clinical study concluding, “Quercetin statistically shortens the timing of molecular test conversion from positive to negative, reducing at the same time symptoms severity and negative predictors of COVID-19.”
I must add the standard and necessary disclaimer that I am not anti-vaccine, having been personally vaccinated in 2020. Nor am I offering medical advice. Any medical treatment, including over-the-counter supplements, should be used only after due diligence and/or in consultation with one’s own physician. Sorry, but this is a necessary paragraph.
Four scientific papers, yet crickets from the media. The last two studies show quercetin reduced “symptom severity,” meaning the difference between a cold one can recover from at home versus a trip to the hospital or worse, that one might not recover from. Isn’t this what vaccines do?
The CDC tells us that the COVID vaccines “help keep you from getting seriously ill.” This is what the quercetin studies found as well. One approach is mandated, a vaccine, a medical intervention, with loss of job, travel, and freedom if you refuse. The other approach, a supplement taken once or twice a day, something readily available at any grocery or health food store, one of myriad supplements on the shelf, is ignored.
What can’t be ignored is that after a year and a half, COVID is still with us. In my home state of Colorado, 78 percent of adults and 63 percent of the 12-and-over population currently have had at least one vaccine dose. Yet at the same time the Denver Post ran this headline, words I haven’t seen since the spring of 2020, “Colorado could stop elective surgeries, activate crisis standards next week if COVID numbers don’t improve.”
It’s clear that COVID is not over, and in some locations is far from it. There will be variants and surges. Meanwhile, the world is upside down from long lockdowns, business closures, masks, quarantines, testing, vaccinations, and finger-wagging from the media who always promise that if we do what they say all will be good. Yet it is not.
We are long past all-hands-on-deck time. Anything we can throw at the COVID beast that might have some benefit, including quercetin and other previously mentioned therapeutics, should be heralded, not maligned, or ignored. Instead, we are on a one-speed bike, pedaling into a strong headwind, guided by the corporate media, big pharma, and a politically motivated medical establishment, making only slow progress, seemingly oblivious to the costs in human suffering.
Which leads me to ask, has this been only about the virus or something else?
Brian C. Joondeph, M.D., is a physician and writer. On Twitter as @retinaldoctor.
<<<
>>> Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
medRxiv
Aug 25, 2021
https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1
Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon
doi: https://doi.org/10.1101/2021.08.24.21262415
Abstract
Background Reports of waning vaccine-induced immunity against COVID-19 have begun to surface. With that, the comparable long-term protection conferred by previous infection with SARS-CoV-2 remains unclear.
Methods
We conducted a retrospective observational study comparing three groups:
(1)SARS-CoV-2-naïve individuals who received a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine,
(2)previously infected individuals who have not been vaccinated, and
(3)previously infected and single dose vaccinated individuals.
Three multivariate logistic regression models were applied. In all models we evaluated four outcomes: SARS-CoV-2 infection, symptomatic disease, COVID-19-related hospitalization and death. The follow-up period of June 1 to August 14, 2021, when the Delta variant was dominant in Israel.
Results
SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021. The increased risk was significant (P<0.001) for symptomatic disease as well. When allowing the infection to occur at any time before vaccination (from March 2020 to February 2021), evidence of waning natural immunity was demonstrated, though SARS-CoV-2 naïve vaccinees had a 5.96-fold (95% CI, 4.85 to 7.33) increased risk for breakthrough infection and a 7.13-fold (95% CI, 5.51 to 9.21) increased risk for symptomatic disease. SARS-CoV-2-naïve vaccinees were also at a greater risk for COVID-19-related-hospitalizations compared to those that were previously infected.
Conclusions
This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity. Individuals who were both previously infected with SARS-CoV-2 and given a single dose of the vaccine gained additional protection against the Delta variant.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no external funding for the project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the MHS (Maccabi Healthcare Services) Institutional Review Board (IRB). Due to the retrospective design of the study, informed consent was waived by the IRB, and all identifying details of the participants were removed before computational analysis.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The authors declare they have no conflict of interest.
Funding: There was no external funding for the project.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Preprint discussion sites covering this article:
PubPeer, 30 Aug 2021
Blog posts linking to this article:
Cafe Hayek, 03 Nov 2021
(Don Boudreaux) TweetMartin Kulldorff reviews two studies on Covid immunity. Here’s his opening: How effective is immunity…
ABC Religion, 13 Oct 2021
This week, Sydneysiders got their first taste of freedom since lockdown began. But not everyone was able to participate: rules…
Oregon Health & Sciences University, 12 Oct 2021
In a story examining whether those who survive COVID-19 should also get vaccinated Fikadu Tafesse, Ph.D., at OHSU notes those…
Cafe Hayek, 06 Oct 2021
(Don Boudreaux) TweetPhil Magness and James Harrigan commemorate the one-year anniversary of the release of the deeply…
Climate Science, 04 Oct 2021
Lockdowns, school closures, mask mandates, and all of the Covid-19 pandemic restrictive policies societies were subjected to…
Healthy Debate, 04 Oct 2021
The post How good is natural immunity? appeared first on Healthy Debate.
Science-Based Medicine, 04 Oct 2021
Antivaxxers have long appealed to "natural immunity" as being somehow inherently superior to vaccine-induced immunity, which is…
Cafe Hayek, 02 Oct 2021
(Don Boudreaux) TweetZach Weissmueller reports on a coalition of California business owners who earlier defied strongman…
Cafe Hayek, 12 Sep 2021
(Don Boudreaux) TweetHarrison Pitt draws lessons for 2020-2021 from Hayek’s 1944 book, The Road to Serfdom. Two slices…
Power LinePower Line, 11 Sep 2021
(John Hinderaker) Joe Biden’s unconstitutional order mandating vaccinations and testing is irrational for several reasons, not…
Climate Science, 11 Sep 2021
Babylon…
Iowa Climate, 10 Sep 2021
Babylon…
Joanne Nova, 10 Sep 2021
Babylon Bee Biden announced that all companies with 100 employees must enforce mandatory vaccination. People will have the…
Nutri-Link Ltd - Clinical Education, 10 Sep 2021
Reading Time: 10 minutesThe obvious answer is NO, otherwise no one would suffer immune related illness and death. The ability…
BeScienced, 08 Sep 2021
Charlotte Thålin, Karolinska…
Naked Science, 07 Sep 2021
<img src="https://naked-science.ru/wp-content/uploads/2021/09/F210812YS17.jpg" alt="????? ????????? ????? ??????? — ?????????????…
SciPhile, 04 Sep 2021
?????? ????? ????? ???????? ?? ???? ????? ????? ??? ???? ????? ????? ?????? ??????? ??? ????? ???? ?????, 1 ??????? 2021, ????? ?…
Climate Science, 03 Sep 2021
The political and media messaging about the coronavirus prevents the citizenry from connecting the dots and realizing how fear…
Iowa Climate, 03 Sep 2021
The political and media messaging about the coronavirus prevents the citizenry from connecting the dots and realizing how fear…
Science Matters Blog, 03 Sep 2021
The political and media messaging about the coronavirus prevents the citizenry from connecting the dots and realizing how fear…
Front Line Genomics, 03 Sep 2021
Check out our summary of some of the latest news and research surrounding COVID-19 from the past fortnight. …
Paul Craig Roberts, 01 Sep 2021
Israeli Medical Researchers Conclude that natural immunity is far superior to vaccine-induced immunity and has no devastating…
William M. Briggs, 31 Aug 2021
Once again, I beg you will forgive the use of the words vexxine and vexxinated. They are an attempt to avoid censor bots and…
Qubit, 31 Aug 2021
Amikor minél több embert kellene meggyozni arról, hogy oltassa be magát a koronavírus ellen a fertozés súlyos következményeit…
Denník N, 30 Aug 2021
Kalkulácia, že sa clovek schválne vystaví koronavírusu, aby získal lepšiu imunitu ako po ockovaní, sa nemusí vyplatit, lebo clove…
Statistical Modeling, Causal Inference, and Social Science, 30 Aug 2021
Joe Stover writes: I came across this article that finds vaccinated individuals are 8 to 21x more susceptible to the Delta…
naked capitalism, 28 Aug 2021
ZME Science, 27 Aug 2021
This shouldn't be taken as a licence to get infected on purpose.
SPECIALTIES, 27 Aug 2021
Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections …
Jeremy's Blog, 27 Aug 2021
Why make these Covid posts? Isn't the Internet saturated with hot takes already? Am I really adding anything here? I think the…
Whats New, 26 Aug 2021
Natural immunity against Covid infection could be stronger than vaccination when protecting against Delta variant: Recovered…
Climate Science, 26 Aug 2021
A shocking new study from Israel compares the protection offered by vaccine-induced immunity versus natural immunity from a…
Iowa Climate, 26 Aug 2021
A shocking new study from Israel compares the protection offered by vaccine-induced immunity versus natural immunity from a…
No Trick Zone, 26 Aug 2021
A shocking new study from Israel compares the protection offered by vaccine-induced immunity versus natural immunity from a…
naked capitalism, 26 Aug 2021
<<<
>>> The novel coronavirus’ spike protein plays additional key role in illness
Salk researchers and collaborators show how the protein damages cells, confirming COVID-19 as a primarily vascular disease
SALK NEWS
April 30, 2021
https://www.salk.edu/news-release/the-novel-coronavirus-spike-protein-plays-additional-key-role-in-illness/
The novel coronavirus’ spike protein plays additional key role in illness
Salk researchers and collaborators show how the protein damages cells, confirming COVID-19 as a primarily vascular disease
LA JOLLA—Scientists have known for a while that SARS-CoV-2’s distinctive “spike” proteins help the virus infect its host by latching on to healthy cells. Now, a major new study shows that the virus spike proteins (which behave very differently than those safely encoded by vaccines) also play a key role in the disease itself.
The paper, published on April 30, 2021, in Circulation Research, also shows conclusively that COVID-19 is a vascular disease, demonstrating exactly how the SARS-CoV-2 virus damages and attacks the vascular system on a cellular level. The findings help explain COVID-19’s wide variety of seemingly unconnected complications, and could open the door for new research into more effective therapies.
Representative images of vascular endothelial control cells (left) and cells treated with the SARS-CoV-2 Spike protein (right) show that the spike protein causes increased mitochondrial fragmentation in vascular cells.
“A lot of people think of it as a respiratory disease, but it’s really a vascular disease,” says Assistant Research Professor Uri Manor, who is co-senior author of the study. “That could explain why some people have strokes, and why some people have issues in other parts of the body. The commonality between them is that they all have vascular underpinnings.”
Salk researchers collaborated with scientists at the University of California San Diego on the paper, including co-first author Jiao Zhang and co-senior author John Shyy, among others.
While the findings themselves aren’t entirely a surprise, the paper provides clear confirmation and a detailed explanation of the mechanism through which the protein damages vascular cells for the first time. There’s been a growing consensus that SARS-CoV-2 affects the vascular system, but exactly how it did so was not understood. Similarly, scientists studying other coronaviruses have long suspected that the spike protein contributed to damaging vascular endothelial cells, but this is the first time the process has been documented.
In the new study, the researchers created a “pseudovirus” that was surrounded by SARS-CoV-2 classic crown of spike proteins, but did not contain any actual virus. Exposure to this pseudovirus resulted in damage to the lungs and arteries of an animal model—proving that the spike protein alone was enough to cause disease. Tissue samples showed inflammation in endothelial cells lining the pulmonary artery walls.
The team then replicated this process in the lab, exposing healthy endothelial cells (which line arteries) to the spike protein. They showed that the spike protein damaged the cells by binding ACE2. This binding disrupted ACE2’s molecular signaling to mitochondria (organelles that generate energy for cells), causing the mitochondria to become damaged and fragmented.
Previous studies have shown a similar effect when cells were exposed to the SARS-CoV-2 virus, but this is the first study to show that the damage occurs when cells are exposed to the spike protein on its own.
“If you remove the replicating capabilities of the virus, it still has a major damaging effect on the vascular cells, simply by virtue of its ability to bind to this ACE2 receptor, the S protein receptor, now famous thanks to COVID,” Manor explains. “Further studies with mutant spike proteins will also provide new insight towards the infectivity and severity of mutant SARS CoV-2 viruses.”
The researchers next hope to take a closer look at the mechanism by which the disrupted ACE2 protein damages mitochondria and causes them to change shape.
Other authors on the study are Yuyang Lei and Zu-Yi Yuan of Jiaotong University in Xi’an, China; Cara R. Schiavon, Leonardo Andrade, and Gerald S. Shadel of Salk; Ming He, Hui Shen, Yichi Zhang, Yoshitake Cho, Mark Hepokoski, Jason X.-J. Yuan, Atul Malhotra, Jin Zhang of the University of California San Diego; Lili Chen, Qian Yin, Ting Lei, Hongliang Wang and Shengpeng Wang of Xi’an Jiatong University Health Science Center in Xi’an, China.
The research was supported by the National Institutes of Health, the National Natural Science Foundation of China, the Shaanxi Natural Science Fund, the National Key Research and Development Program, the First Affiliated Hospital of Xi’an Jiaotong University; and Xi’an Jiaotong University.
DOI: 10.1161/CIRCRESAHA.121.318902
<<<
>>> COVID-19 is a vascular disease not a respiratory one, says study
Euronews
By Rafael Cereceda
20/08/2021
https://www.euronews.com/2021/05/06/covid-19-is-a-vascular-disease-not-a-respiratory-one-says-study
Healthy endothelial cells (left) and those treated with coronavirus protein S (right) show mitochondrial fragmentation in the vascular system.
A study at the University of San Diego claims to have proof that COVID-19 is not a respiratory illness, but a vascular one.
This could explain blood clots in some COVID patients and other issues like "COVID feet", which are not classic symptoms of a respiratory illness.
The study, published in the journal Circulation Research, shows with precision how virus damages the cells of the vascular system.
It was already known that besides the various symptoms of COVID-19 that coincide with respiratory problems, there are other cardiovascular issues that affect other parts of the body.
What’s new is the team conducting the study, which included scientists from the SALK Institute, showed the form in which the virus attacks the vascular or circulatory system.
The S protein of the virus, the spike that forms the crown, attacks the receptor ACE2, damaging the mitocondrias that generate the energy of the cells, thus damaging the endothelium, which lines the blood vessel.
This is something that has already been observed, but what wasn’t previously known is the exact mechanism and role of the S protein.
This protein is replicated by all of the currently available vaccines.
The scientists created a pseudovirus for the study, which only had the S protein but not the rest of the virus, to show in the lab that this protein is enough by itself to cause disease.
The effects on the respiratory system are a consequence of the inflammation of the vascular tissue in the lungs.
“A lot of people think of it as a respiratory disease, but it’s really a vascular disease,” says assistant research professor Uri Manor, who is co-senior author of the study.
“That could explain why some people have strokes, and why some people have issues in other parts of the body. The commonality between them is that they all have vascular underpinnings.”
Only an effect in serious cases?
Professor Rafael Máñez Mendiluce, who has been treating COVID-19 patients for a year as head of intensive care at Bellvitge University Hospital, says this is no surprise, given the clinical pictures presented by those who come to his department.
A year ago, he explained to us that the greatest risk of COVID-19 was the inflammatory symptoms presented by the patients. He also reminded us that blood clots are phenomena that occur in other viruses.
Máñez Mendiluce also wonders whether vascular problems do not occur only in the most severe patients, once the infection has already "conquered" the respiratory tract, spreading through the blood.
"Generally in mild patients, the infection is limited to the upper airways only,” he says.
He also believes the vascular problem could be related to the inflammatory response of the patient's immune system.
For Máñez Mendiluce, who has 30 years of experience in intensive care, this discovery does not drastically change the treatment possibilities for the most severe cases. He recalls that antithrombotic drug treatments have not proven to be particularly effective and that for the time being it is recommended to focus on the inflammation caused by the immune response.
This is a long-standing problem in intensive care. "We still don't have any treatment for thrombosis caused by the inflammatory response generated by the infection," he explains.
The discussion in the scientific community is still open, he adds. These problems are recurrent in intensive care units.
Máñez Mendiluce thinks this study does not call into question existing vaccines, although it should be better understood why the AstraZeneca and Johnson & Johnson vaccines have caused some rare cases of blood clotting.
The discovery has caused a stir. Some wonder whether it is dangerous for vaccines to inoculate precisely replicas of the S protein that appears to be capable of causing the disease.
Professor Uri Manor said on his Twitter account that, contrary to anti-vaccine claims, the study only shows that COVID-19 is a very insidious disease.
He explains that the amount of S protein in the vaccines is too small to be problematic.
He also says that the messenger RNA vaccine is much safer than getting the disease. "Everyone should get it, I did and everyone in my family did! Our paper just shows that this disease really sucks.
The Salk Institute researchers now hope to better understand the mechanism by which ACE2 receptors damaged by the S protein cause deformations and damage to mitochondria, which then cause problems in vascular tissue.
<<<
>>> How does Merck's COVID-19 pill compare to Pfizer's?
Reuters
Nov 5, 2021
By Deena Beasley
https://finance.yahoo.com/news/explainer-does-mercks-covid-19-201931832.html
Nov 5 (Reuters) - Pfizer Inc and Merck & Co Inc have developed experimental antiviral pills that have shown promising efficacy in trials of adults with COVID-19 who are at high risk of serious illness. Both drugs also are being studied to see if they can prevent infection in people exposed to the virus.
Here is an explanation of the differences in the two pills.
Which of the new pills works better?
Trial figures provided by the two companies suggest that Pfizer has the more effective pill, but they have not yet offered full data.
Pfizer said on Friday https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-antiviral-pill-cuts-risk-severe-covid-19-by-89-2021-11-05 trial results showed that its pill reduced the chance of hospitalization or death by 89% in COVID-19 patients at risk for severe illness given the treatment within three days of the onset of symptoms and by 85% when given within five days of onset.
Merck on Oct. 1 said https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-cuts-risk-death-hospitalization-by-50-study-2021-10-01 its pill lowered the chance of hospitalization or death by about 50% in patients at risk for severe illness given the treatment within five days of onset. It did not provide figures regarding patients getting the pill within three days of onset.
Pfizer's drug has the brand name Paxlovid. Merck's drug has the brand name Lavgevrio in Britain, where it has won regulatory approval https://www.reuters.com/business/healthcare-pharmaceuticals/britain-approves-mercks-oral-covid-19-pill-2021-11-04.
Why are these drugs important?
While a number of vaccines are available worldwide to prevent infection including one made by Pfizer, there are limited treatment options for people infected with COVID-19.
Currently, COVID-19 patients who are not sick enough to be hospitalized but are at risk of serious illness can be treated with antibody drugs, though they have to be given intravenously at hospitals or infusion centers.
How do they work?
Both drugs are given for five days. Pfizer's regimen is three pills in the morning and three pills at night. Merck's drug is taken as four pills in the morning and four at night.
Pfizer's drug is part of a class known as protease inhibitors designed to block an enzyme that the coronavirus needs to multiply. Pfizer said that because the drug targets a part of the virus essential to replication, the pathogen cannot become resistant to the treatment.
Pfizer's drug is given in combination with ritonavir, an older antiviral that boosts the activity of protease inhibitors but can cause gastrointestinal side effects and interfere with other medications.
Merck's pill, developed with Ridgeback Biotherapeutics, is a nucleoside analogue with a mechanism of action that aims to introduce errors into the genetic code of the virus. Because the drug generates random mutations into the virus, it is difficult for the coronavirus to evolve and become resistant.
What do we know about safety?
Both companies have released only limited data on the treatments, but expressed confidence in their safety.
Pfizer said about 20% of patients who received either the pill or a placebo experienced adverse events, mostly mild. Serious side effects were reported by 1.7% of patients receiving the drug and 6.6% of placebo patients.
Merck said 12% of patients receiving its drug and 11% of placebo patients experienced drug-related adverse events.
Drugs in the same class as Merck's pill have been linked to birth defects in animal studies. Merck has said similar studies of its drug - for longer and at higher doses than used in humans - show that it does not cause birth defects or cancer.
What do we know about supplies?
Pfizer and Merck have said they are making efforts to expand global access to the drugs. Pfizer said it expects to produce more than 180,000 courses of its therapy by the end of this year, with production of at least 50 million planned for 2022. Merck has said it expects to produce 10 million courses of its drug by the end of this year, with at least 20 million set to be manufactured in 2022.
Which costs more?
The U.S. government provides vaccines and treatments for COVID-19 for free to U.S. residents. Countries around the world are negotiating prices with Pfizer and Merck.
President Joe Biden on Friday said the U.S. government has secured millions of doses of Pfizer's treatment. Merck has a $1.2 billion contract to supply the United States with 1.7 million courses of its drug - or about $700 per course.
Britain has secured 250,000 courses of Pfizer's drug, but prices for the British contracts have not been made public.
<<<
>>> Effect of SARS-CoV-2 proteins on vascular permeability
eLife
https://elifesciences.org/articles/69314
Rossana Rauti, Meishar Shahoha, Yael Leichtmann-Bardoogo, Rami Nasser, Eyal Paz, Rina Tamir, Victoria Miller, Tal Babich, Kfir Shaked see all
Department of Biomedical Engineering, Tel Aviv University, Israel; School of Neurobiology, Biochemistry and Biophysics, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel; Sagol School of Neuroscience, Tel Aviv University, Israel; Blavatnik School of Computer Science, Tel Aviv University, Israel; Grass Center for Bioengineering, The Hebrew University of Jerusalem, Israel; The Center for Nanoscience and Nanotechnology, Tel Aviv University, Israel
Research Article Oct 25, 2021
Cited 0 Views 2,735 Annotations 0
DOI: 10.7554/eLife.69314
Article
Figures and data
Abstract
Severe acute respiratory syndrome (SARS)-CoV-2 infection leads to severe disease associated with cytokine storm, vascular dysfunction, coagulation, and progressive lung damage. It affects several vital organs, seemingly through a pathological effect on endothelial cells. The SARS-CoV-2 genome encodes 29 proteins, whose contribution to the disease manifestations, and especially endothelial complications, is unknown. We cloned and expressed 26 of these proteins in human cells and characterized the endothelial response to overexpression of each, individually. Whereas most proteins induced significant changes in endothelial permeability, nsp2, nsp5_c145a (catalytic dead mutant of nsp5), and nsp7 also reduced CD31, and increased von Willebrand factor expression and IL-6, suggesting endothelial dysfunction. Using propagation-based analysis of a protein–protein interaction (PPI) network, we predicted the endothelial proteins affected by the viral proteins that potentially mediate these effects. We further applied our PPI model to identify the role of each SARS-CoV-2 protein in other tissues affected by coronavirus disease (COVID-19). While validating the PPI network model, we found that the tight junction (TJ) proteins cadherin-5, ZO-1, and ß-catenin are affected by nsp2, nsp5_c145a, and nsp7 consistent with the model prediction. Overall, this work identifies the SARS-CoV-2 proteins that might be most detrimental in terms of endothelial dysfunction, thereby shedding light on vascular aspects of COVID-19.
Introduction
Coronavirus disease (COVID-19) caused by the 2019 novel coronavirus (2019-nCoV/SARS-CoV-2) led to a global pandemic in 2020. By late September 2021, coronavirus had infected more than 220 million people worldwide, causing over 4.5 million deaths. After the initial phase of the viral infection, ~ 30% of patients hospitalized with COVID-19 develop severe disease with progressive lung damage, known as severe acute respiratory syndrome (SARS), and a severe immune response. Interestingly, additional pathologies have been observed, such as hypoxemia and cytokine storm which, in some cases, lead to heart and kidney failure, and neurological symptoms. Recent observations suggest that these pathologies are mainly due to increased coagulation and vascular dysfunction (Lee et al., 2021; Libby and Lüscher, 2020; Siddiqi et al., 2020). It is currently believed that in addition to being a respiratory disease, COVID-19 might also be a ‘vascular disease’ (Lee et al., 2021), as it may result in a leaky vascular barrier and increased expression of von Willebrand factor (VWF) (Siddiqi et al., 2020), responsible for increased coagulation, cytokine release, and inflammation (Siddiqi et al., 2020; Teuwen et al., 2020; Aid et al., 2020; Potus et al., 2020; Wazny et al., 2020; Pum et al., 2021; Barbosa et al., 2021; Lin et al., 2020; Matarese et al., 2020; Xiao et al., 2020). Recent studies suggest that the main mechanism disrupting the endothelial barrier occurs in several stages: First, a direct effect on the endothelial cells that causes an immune response of the vascular endothelium (endotheliitis) and endothelial dysfunction. Second, lysis and death of the endothelial cells Teuwen et al., 2020; Xiao et al., 2020 followed by sequestering of human angiotensin I-converting enzyme 2 (hACE2) by viral spike proteins that activate the kallikrein–bradykinin and renin–angiotensin pathways, increasing vascular permeability (Teuwen et al., 2020; Varga et al., 2020). Last, overreaction of the immune system, during which a combination of neutrophils and immune cells producing reactive oxygen species, inflammatory cytokines (e.g., interleukin [IL]-1ß, IL-6, and tumor necrosis factor), and vasoactive molecules (e.g., thrombin, histamine, thromboxane A2, and vascular endothelial growth factor), and the deposition of hyaluronic acid lead to disruption of endothelial junctions, increased vascular permeability, and leakage and coagulation (Libby and Lüscher, 2020; Teuwen et al., 2020; Varga et al., 2020). Of great interest is the effect on the brain’s vascular system. Cerebrovascular effects have been suggested to be among the long-lasting effects of COVID-19. Indeed, the susceptibility of brain endothelial cells to direct SARS-CoV-2 infection was found to increase due to increased expression of hACE2 in a blood flow-dependent manner, leading to a unique gene expression process that might contribute to the cerebrovascular effects of the virus (Pober and Sessa, 2007).
While many studies point out the importance of the vascular system in COVID-19 (Kaneko et al., 2021; Jung et al., 2020b; Nägele et al., 2020), only a few Pons et al., 2020; Chioh et al., 2020; Nascimento Conde et al., 2020; Buzhdygan et al., 2020 have looked at the direct vascular response to the virus. Most of those reports stem from either clinical observations, or in vitro studies or in vivo studies in which animals/cells were transfected with the SARS-CoV-2 virus and their systemic cellular response assessed, without pinpointing the specific viral protein(s) causing the observed changes. SARS-CoV-2 is an enveloped virus with a positive-sense, single-stranded RNA genome of ~30 kb, encoding 29 proteins (Figure 1). These proteins can be classified as: structural proteins: S (spike proteins), E (envelope proteins), M (membrane proteins), N (nucleocapsid protein and viral RNA); nonstructural proteins: nsp1–16; open reading frame accessory proteins: orf3–10 (Kim et al., 2020; Hu et al., 2021). Table 1 summarizes the known effects of specific SARS-CoV-2 proteins (Gordon et al., 2020; Peng et al., 2020b; Procko, 2020; Cornillez-Ty et al., 2009; Romano et al., 2020; Hillen et al., 2020; Chi et al., 2003). The functionality of some of these is still unknown. Moreover, a considerable knowledge gap still exists regarding molecular mechanisms, especially the protein–protein interaction (PPI) pathways (Cowen et al., 2017), leading to tissue dysfunction.
(See original article for detailed list of (SARS)-CoV-2 proteins)
https://elifesciences.org/articles/69314
To tackle these challenges, we cultured human umbilical vein endothelial cells (HUVECs) and systematically transduced them with lentiviral particles encoding 26 out of the 29 viral proteins, separately. The three remaining genes were not included in this study purely for technical reasons. We then examined their effects on HUVEC monolayer permeability and the expression of factors involved in vascular permeability and coagulation. The results were analyzed in the context of virus–host and host–host PPI networks. By combining the insights from the experimental and computational results, we generated a model that explains how each of the 26 proteins of SARS-CoV-2, including a mutated form of nsp5, the catalytic dead mutant termed nsp5_c145a, affects the protein network regulating vascular functionality. Moreover, once the PPI model was validated with our experimental data, we applied it to more than 250 proteins that have been identified in the literature as affected by the SARS-CoV-2 proteins. This enabled us to pinpoint the more dominant SARS-CoV-2 proteins and chart their effects. Overall, this work shows how each of the SARS-CoV-2 proteins differentially affects vascular functionality; moreover, once the model was validated, we applied it to identify how SARS-CoV-2 proteins interact with proteins that have been significantly correlated with changes in cell functionality.
Results
SARS-CoV-2 proteins impair barrier properties affecting cell-junction proteins
Increasing numbers of studies indicate a significant role for the vasculature in the physiological response to SARS-CoV-2. However, neither the exact molecular mechanism that leads to these effects nor the individual contribution of any of the SARS-CoV-2 proteins is known. Plasmids encoding SARS-CoV-2 proteins were cloned into lentivirus vectors, with eGFP-encoding vector used as a negative control. To shed light on the vascular response to the virus, HUVECs were cultured on different platforms, transduced with these lentiviral particles, and assessed for the effects of the virus proteins on different functionalities. Culturing HUVEC on Transwells or glass coverslips (Figure 2a) allowed us to identify how the specific proteins affect endothelial functionality. To ensure proper infection, the control vector included a GFP label, which enabled us to estimate infection efficiency at around 70 % (Figure 2a). Since the most basic function of the endothelium is to serve as a barrier, we sought to identify the changes in endothelium permeability in response to the SARS-CoV-2 proteins, and to pinpoint which of these proteins have the most significant effect. Barrier functions and properties were measured via trans-epithelial-endothelial electrical resistance (TEER), a standard method that identifies changes in impedance values, reflecting the integrity and permeability of the cell monolayer (Srinivasan et al., 2015). The GFP control and nine SARS-CoV-2 proteins did not show any significant change in TEER values (compared to the untreated condition), whereas 18 of the SARS-CoV-2 proteins caused significant changes in value (see plot in Figure 2b). The most dominant permeability changes were observed with nsp5_c145a, nsp13, nsp7, orf7a, and nsp2, with a 20–28% decrease in TEER values (Figure 2—figure supplement 1, and Figure 2c), in which the different SARS-CoV-2 proteins are listed and the gradual color change from red to violet represents the progressive reduction in TEER values. Figure 2—figure supplement 1 shows the comparison in TEER values before the infection and 3 and 4 days after the infection, showing that the permeability changes in the cells exposed to the viral proteins are maintained.
Next, we analyzed some of the proteins that exhibited the most significant (nsp2, nsp5_c145a, and nsp7) or least significant (S) changes in TEER value for changes in expression of the cell-junction proteins such as CD31 (Figure 2d and e), cadherin 1–5, occludin, and ZO 1–3 (presented later), indicating altered barrier functions. Analysis of the immunocytochemistry (ICC) (Figure 2d and e) showed, as expected, that nsp2, nsp5_c145a, and nsp7 significantly reduce the expression levels of CD31 compared to the untreated, eGFP, and S conditions, suggesting a deterioration in barrier function. Hence, these data show a differential effect of SARS-CoV-2 proteins on endothelial functionality and provide a mechanistic explanation for the reduction in endothelial integrity.
Increased endothelial inflammatory response caused by SARS-CoV-2 proteins
It is known that SARS-CoV-2 can cause a severe cytokine storm (Pum et al., 2021; Wang et al., 2020a) and a significant increase in coagulation-related pathologies. As we were interested in identifying the role of the vasculature in these observations, we stained and analyzed the expression level of VWF (Figure 3a and b), which is highly correlated with coagulation (Rietveld et al., 2019). Similar to the CD31 staining, we characterized only those proteins that resulted in a significant decrease in TEER values (nsp2, nsp5_c145a, and nsp7). As shown in Figure 3a and b, the control samples did not exhibit marked expression of VWF, whereas the cells transfected with nsp2, nsp5_c145a, and nsp7 showed a significant change in VWF expression. Moreover, as VWF is also associated with increased inflammation (Kawecki et al., 2017), we monitored changes in cytokine expression due to the different SARS-CoV-2 proteins (Figure 3c). We were particularly interested in IL-6, which has been identified as one of the most dominant cytokines expressed due to SARS-CoV-2 infection (Wang et al., 2020a; Akbari and Rezaie, 2020; Peruzzi et al., 2020; Liao et al., 2020b; Liao et al., 2020a). We observed that 13 out of the 26 proteins caused an increase in IL-6 secretion, 3 of which had resulted in a decrease in barrier function and increased VWF expression.
Correlation between vascular permeability impairment and viral proteins
We then investigated how SARS-CoV-2 causes the observed changes in HUVECs permeability. We collected sets of proteins responsible for specific functionalities of endothelial cells. We also constructed an integrated viral–host and host–host PPI network. For each viral protein and each prior functional set, we measured the network proximity between the viral protein and the human functional set using a network propagation algorithm. We scored the significance of these propagation calculations by comparing them to those obtained on random PPI networks with the same node degrees. Proteins receiving high and significant scores were most likely to interact with the specific SARS-CoV-2 protein and thus might cause the observed functional changes. When comparing the overall effects of the 26 SARS-CoV-2 proteins on endothelial TJ proteins (e.g., cadherin 1–5, occludin, and ZO 1–3), we found a correlation between the effects of the SARS-CoV-2 proteins and TEER values (Figure 4a). Moreover, some of the proteins that significantly affected the TEER parameters (Figure 2c) were also observed to be significantly proximal to the permeability-related set. These included nsp2, nsp7, and nsp13 (Figure 4a). Our algorithm identified cadherin-2, a-catenin, ß-catenin, d-catenin, and ZO 1 and 2 as the most susceptible proteins to SARS-CoV-2 infection (Figure 4b).
To validate our PPI network model, we performed immunostaining of some TJ proteins (ß-catenin, cadherin-5, ZO-1, and occludin) of HUVEC transfected with viral proteins and to compare it to the model prediction. Similar to the CD31 staining, we characterized only those proteins that significantly decreased TEER values (nsp2, nsp5_c145a, and nsp7) compared to the eGFP and untreated condition (Figure 5). As shown in Figure 5a–c, the cells transfected with nsp2, nsp5_c145a, and nsp7 showed a significant reduction in the ß-catenin, cadherin-5, and ZO-1 intensity, confirming the ability of the SARS-CoV-2 proteins to impair endothelial permeability.
Once the model was validated, we used it to identify how the individual SARS-Cov-2 proteins affect nine other different vascular endothelial cells. As a starting point, we created a table (Table 2) (based on the literature) where we compared the expression of 12 different TJ proteins across nine different types of endothelial cells. We then applied the network-based model to identify which endothelial cells are more susceptible to the different SARS-Cov-2 proteins. As can be seen in Figure 6, there are significant differences in the response of various viral proteins on different types of vascular endothelial cells. For example,, the viral proteins nsp13, nsp11, orf6, and S seem to have a significant effect on the different types of vascular endothelial cells, according to the network score detected. However, the proteins m, E, n, nsp12, and nsp8 are the less interactive with the vascular cells.
(see original article for table) -
https://elifesciences.org/articles/69314
As our network propagation model is highly correlated with our experimental results, we applied it to other physiological systems that are known to be affected by SARS-CoV-2. We created a list of all proteins that are known to be affected by the SARS-CoV-2 proteins according to the literature (Supplementary file 1A, white columns). The table was composed of both proteins identified experimentally via western blot, proteomics, and immunohistochemistry (marked in blue) and those identified clinically as being highly correlated with loss of specific functionality in specific tissues (marked in red). We then applied the network-based model to identify which proteins in Supplementary file 1A are most susceptible to the different SARS-CoV-2 proteins. As can be seen in Figure 7—figure supplements 2–7, Supplementary file 1A and B, specific SARS-CoV-2 proteins were identified as affecting specific proteins in specific tissues. As expected, most of the SARS-CoV-2 proteins affected more than one protein, the most salient being nsp11, nsp4, and nsp7 (Figure 7b), each of which was predicted to affect more than 40 different proteins. An additional parameter that should be considered is the protein’s ‘distance’ from the viral proteins. This value represents the number of hops in the PPI network from a given protein to the viral proteins, where a value of 1 represents a direct viral–host connection. We hypothesized that the closer the distance between the viral proteins and the given protein, the more significant the viral effect. Supplementary file 1A (gray columns) and Figure 7c present the calculated distances. Most of the identified proteins in Supplementary file 1A were classified with a distance of 1 or 2 from the virus, suggesting more severe putative effects. A very clear example, are the T cells, macrophages, lung epithelial and cardiomyocytes which show that the most significant effect was by the viral proteins which present a close connection with the relative cell proteins reported. This suggest a potential effect on the related functional or metabolic pathway (Supplementary file 1A).
Discussion
Due to the impact of SARS-CoV-2, many studies have looked at the physiological responses to the virus (Lee et al., 2021; Libby and Lüscher, 2020; Siddiqi et al., 2020; Teuwen et al., 2020; Chioh et al., 2020). In this work, we sought to identify how specific SARS-CoV-2 proteins affect the vasculature by assessing the effect of individual SARS-CoV-2 proteins on endothelial cells (HUVEC). This approach has significant advantages: it enables pinpointing and isolating how each of the SARS-CoV-2 proteins independently affects the endothelial response, and directly measuring endothelial functionality. The HUVEC model, derived from the umbilical cord, is physiologically representative of the human vascular endothelium, allowing the study of the physiological and pathological conditions as well as the effects of novel drugs on human endothelium (Bouïs et al., 2001; Medina-Leyte et al., 2020). Among technical advantages, cultured HUVECs are a simple in vitro vascular endothelial model, particularly suitable for studying endothelial properties and dynamics as well as the putative role of adhesion molecules, the synthesis of extracellular proteins and blood vessel maturation (Vailhé et al., 2001).
The current study showed that almost 70 % (18 out of 26) of the SARS-CoV-2 proteins affect endothelial barrier integrity; however, the most significant proteins were nsp2, nsp5_c145a, and nsp7, which also induced upregulated expression of the coagulation factor VWF and cytokine release. These critical facts can shed light on the multiple pathologies observed in SARS-CoV-2 infection, including cytokine storm, increased coagulation and related diseases (e.g., heart attack and stroke) (Lee et al., 2021; Aid et al., 2020), increased cardiovascular disease, and increased neurological symptoms. The results presented here showed an effect of in vitro cultured endothelial cells, which may lead to vasculature leakiness, consequently causing exotoxicity (i.e., the penetration of toxic reagents from the blood into the brain). While there are many parameters associated with functional changes, the use of advanced tools, including network-based analysis, enabled us to elucidate the specific proteins and the specific interactions that are predicted to cause these changes. The PPI network enabled us to predict that the changes observed in barrier function are possibly due to interactions between host proteins such as cadherin 2, a-catenin, ß-catenin, d-catenin, and ZO 1 and 2, and at least with the viral proteins nsp2, nsp5_c145a, and nsp7. Moreover, we validated our PPI model performing further immunostaining analysis demonstrating not only the ability of the viral proteins to strongly impair TJ expression, but also to confirm the data predicted by our model in which some TJ proteins can be more affected than others.
PPI analysis revealed a highly correlated effect of nsp7 and nsp13 on ß-catenin in endothelial cells (Figure 4b; Jung et al., 2020a; Lengfeld et al., 2017). Interestingly, neither nsp2 nor nsp5_c145a affected a high number of proteins (Figure 7b), whereas nsp7 did, as identified by the network. Analyzing the repertoire of SARS-CoV-2 proteins, we see almost no effect of the structural proteins; rather, mostly nonstructural and open reading frame proteins affected HUVEC functionality, manifested as decreased barrier function and increased cytokine secretion (Figures 2 and 3). While the nonstructural proteins are mainly responsible for replicating viral RNA, the open reading frame proteins are related to counteraction with the host immune system; some of these are localized to the mitochondria and have been shown to alter the mitochondrial antiviral signaling pathway (Miller et al., 2021). We found that the proteins most affecting barrier function (decreased TEER and decreased CD31, ß-catenin, cadherin-5, and ZO-1 expression) and cytokine response (IL-6 secretion and VWF expression) were nsp2, nsp5_c145a, and nsp7 (Figure 2; Figure 3; Figure 6); nsp7 forms a replication complex with nsp8 and nsp12 that is essential for viral replication and transcription (Cowen et al., 2017; Peng et al., 2020a). Peng et al., 2020b suggested that in the core polymerase complex nsp7–nsp8–nsp12, nsp12 is the catalytic subunit, and nsp7 and nsp8 function as cofactors. They further suggested that the mechanism of activation mainly involves the cofactors rather than the catalytic subunit (Peng et al., 2020b). This might explain why we saw mainly an effect of the cofactor proteins on endothelial cells and almost no effect of the catalytic subunit. Network interactions Díaz, 2020 have shown that nsp7 has the most interactions with the host, suggesting a potential target for the treatment of COVID-19. Moreover, no mutations were found in nsp7 compared to nsp2 or nsp5_c145a (Kaushal et al., 2020), suggesting a conserved protein with a vital function in virus survival. The nsp13 protein has both helicase activity and 5’ triphosphatase activity, which play an important role in mRNA capping. We saw a significant effect of nsp13 on barrier function, but hardly any effect on cytokine secretion. Chen et al., 2020, suggested functional complexation between nsp8 and nsp12, the RdRp (RNA-dependent RNA polymerase) replication complex, and nsp13. Given the fact that we observed a substantial effect of nsp7 – one of the proteins of the replication complex – and an effect of nsp13 on HUVEC barrier function, complexation of nsp13 with the replication complex might indicate an important role for this complex in the impaired functionality of the HUVECs, and therefore in the propagation of the disease, and the known vascular damage seen in COVID-19 patients. As suggested by our model, nsp13 seems to have a strong effect also on other types of vascular endothelial cells (Figure 6) as well as on all cell types (Figure 7a), positioning nsp13 as one of the main targets for disease treatment.
It is important to note that the comparison between the different endothelial cell types revealed exciting differences in the TJ protein expression, which correlate to the different properties of the different cell types (Nakato et al., 2019). One of the major differences was that some endothelial cell lines do not have cadherin at all (e.g., HAoEC), or very limited amount of cadherin (e.g., HPAEC, HUAEC, HGSVEC). Our model suggests that some endothelial types (e.g., HUVEC, HUAEC, HGSVEC, HCAEC) are more susceptible to the SARS-Cov-2 virus. It, therefore, suggests that the treatment of one type of endothelial cell might be different from another type but offers the PPI model as a tool for initial prediction. Overall, the combination of identifying the differences in the TJ protein expression between the different endothelial cells and the use of the PPI model enabled us to pinpoint the differences in susceptibility to the disease and to identify which specific proteins have the most significant effect.
Many studies have looked at the SARS-CoV-2 interaction with nonpulmonary/nonvascular tissues (e.g., neurons, hepatocytes, immune components such as lymphocytes, macrophages, etc.) (Lee et al., 2021), as pathological studies identified a viral effect on these tissues, despite their very limited amount, or lack of ACE2 receptors. To better understand how SARS-CoV-2 interacts with and affects other tissues, we consolidated all of the proteins currently known to be affected by the virus into Supplementary file 1A. It is interesting to note that the most dominant SARS-CoV-2 proteins are nsp4, nsp11, and nsp7. Davies et al., 2020, identified the interaction of nsp2 with nsp4, both involved in endoplasmic reticulum (ER) calcium signaling and mitochondrial biogenesis. This suggests a new functional role in the host ER and mitochondrial organelle contact process and calcium homeostasis.
By now it is clear that vasculature plays a significant role in the physiological response to the virus. However, it is still unclear how the virus affects the vasculature, and if it can be found in the blood. This is a critical question, as it has significant consequences on the extent of the virus’s ability to affect the vasculature. Current studies demonstrate that the pulmonary vasculature is significantly affected and is one of the dominant triggers for the pathologies mentioned above. However, involvement with the rest of the vasculature is still unclear, as is whether the virus can be found in an active form in the blood circulation (Peng et al., 2020a; Chang et al., 2020; Orologas-Stavrou et al., 2020; Andersson et al., 2020; Escribano et al., 2020; Wang et al., 2020b). Some studies suggest that even if there are traces of SARS-CoV-2 in the blood, it is not in an active form and cannot cause disease or a systemic response (Andersson et al., 2020). On the other hand, some studies suggest that SARS-CoV-2 can be found in the blood, and can induce the disease and cause both cellular and systemic dysfunction (Peng et al., 2020a; Chang et al., 2020; Escribano et al., 2020). While this question is beyond the scope of this work, it is important to note that if future studies do identify the active form of SARS-CoV-2 in human blood, then the implications of our findings will apply to this systemic response as well (Ahmed et al., 2020; Park et al., 2020).
As already noted, the pathology is probably a combination of multiple conditions and pathways activated by the different proteins. However, our findings might open new avenues for future therapeutics. Moreover, most of the proteins that were identified as affected by SARS-CoV-2 had a distance factor of at most three to the human and viral proteins. This coincides with the current dogma, whereby proteins that have a shorter distance between them are more likely to be affected.
While beneficial, our approach has two major limitations: (a) our inability to identify the effect of multiple proteins and (b) our neglect of the effect of the coronavirus structure and binding on the cellular response. The former point can be overcome by expressing combinations of different SARS-CoV-2 proteins. However, since the SARS-CoV-2 expresses 29 proteins, there are about ~9 × 1030 possible protein combinations. Therefore, we decided to focus on individual proteins and allow further studies to pursue any combinations of interest. Regarding the latter limitation, we did not include the coronavirus structure (including the ACE2 receptors) in this study, because many studies have already demonstrated the cellular response to this structure (Chioh et al., 2020; Yang et al., 2020; Procko, 2020), and how tissues that do not have significant ACE2 expression (neurons, immune components such as B and T lymphocytes, and macrophages) are affected by the virus remains an open question.
Conclusions
Accumulating clinical evidence suggests that COVID-19 is a disease with vascular aspects. However, only a few studies have identified the specific role of each of the SARS-CoV-2 proteins in the cellular response leading to vascular dysfunctions. In this work, we characterized the endothelial response to each of 26 SARS-CoV-2 proteins and identified those that have the most significant effect on the barrier function. In addition, we used PPI network-based analysis to predict which of the endothelial proteins is most affected by the virus and to identify the specific role of each of the SARS-CoV-2 proteins in the observed changes in systemic protein expression. Overall, this work identified which of the SARS-CoV-2 proteins are most dominant in their effect on the physiological response to the virus. We believe that the data presented in this work will give us better insight into the mechanism by which the vasculature and the system respond to the virus, and will enable us to expedite drug development for the virus by targeting the identified dominant proteins.
<<<
References -
See original article for extensive references -
https://elifesciences.org/articles/69314
>>> COVID proteins that trigger strokes and heart attacks identified by Israeli team
Times of Israel
by Nathan Jeffay
Nov 3, 2021
Discovery, made through ‘peek in virus’s black box,’ could lead to therapies that halt havoc wrought on vascular system, say Tel Aviv University scientists
https://www.timesofisrael.com/covid-pieces-that-trigger-strokes-and-heart-attacks-identified-by-israeli-team/
Israeli scientists have identified the virus proteins that are triggering strokes and heart attacks in COVID-19 patients, in a breakthrough they expect will pave the way for new drugs.
The scientists made the discovery by taking a “peek in the virus’s black box,” Dr. Ben Maoz of Tel Aviv University told The Times of Israel, explaining that his team analyzed all 29 proteins of the virus to figure out which of them are wreaking havoc in the vascular system.
“Coronavirus isn’t the purely respiratory disease we first thought, and we have identified the proteins that put patients at increased risk of stroke, heart attack, and other problems associated with the vascular system,” Maoz said.
He identified the five proteins in SARS-CoV-2 that lead to vascular problems in the peer-reviewed journal eLife.
“This work could well help scientists to develop drugs to counter the effect of the coronavirus on the vascular system, by providing an understanding of exactly which proteins, or pieces of the virus, are causing problems,” said Maoz.
His lab, which focuses on biomedical engineering and neuroscience, collaborated with Prof. Uri Ashery and other Tel Aviv University researchers to create a simulation of a human vascular system and observe the impact of all 29 coronavirus proteins. From their analysis, they were able to identify which of them affected the vascular system — and how.
“We have not only discovered which proteins have an impact on the vascular system, but also seen how exactly they exert their effect,” said Maoz. “What we found is these specific proteins make your vasculature more leaky. The tubes become more porous and cannot hold liquid as you would hope. This information is also valuable in efforts to develop drugs.”
Maoz hopes to lay foundations for more nuanced treatment of coronavirus.
“To this day the virus has been treated as one entity, despite the fact that it affects different parts of the body in different ways,” he said.
“All the evidence shows that the virus severely damages the blood vessels or the endothelial cells that line the blood vessels. I hope that our research will prove useful in enabling more targeted treatment.”
<<<
>>> Database Lock Completed for Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19
Accesswire
November 3, 2021
https://finance.yahoo.com/news/database-lock-completed-innovation-pharmaceuticals-113000231.html
WAKEFIELD, MA / ACCESSWIRE / November 3, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical-stage biopharmaceutical company, today announced that the Company has received confirmation that hard lock of the database was completed for its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Statistical analysis is underway, with topline results for the trial anticipated to be reported during the week of November 8, 2021.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical-stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases.
<<<
>>> Fluvoxamine: Cheap, generic anti-depressant called Luvox may reduce severe Covid-19 disease, study finds
10-28-21
By Maggie Fox
CNN
https://www.msn.com/en-us/health/medical/fluvoxamine-cheap-generic-anti-depressant-called-luvox-may-reduce-severe-covid-19-disease-study-finds/ar-AAQ2b8B?ocid=uxbndlbing
A cheap, generically available anti-depressant may reduce the risk of severe Covid-19 disease by close to a third in people at high risk, researchers reported Wednesday.
A trial among about 1,500 patients in Brazil showed those who took the drug, known as fluvoxamine, were less likely to progress to severe disease and to require hospitalization.
The drug, sold under the brand name Luvox, is a selective serotonin reuptake inhibitor (SSRI) most often used to treat obsessive compulsive disorder (OCD) and depression. But it can affect inflammation, said Dr. Angela Reiersen, an associate professor of psychiatry at Washington University in St. Louis who worked on the study, published in The Lancet Global Health.
"Fluvoxamine?may reduce the production of inflammatory molecules called cytokines, that can be triggered by SARS-CoV-2 infection," Reiersen said in a statement. The drug may also reduce blood platelets, which may affect the clotting effects of coronavirus infection.
Reierson and colleagues gave 741 volunteers with Covid-19 100 mg of?fluvoxamine?twice a day for 10 days while 756 volunteers got a placebo.
Among the patients who got fluvoxamine, 79 -- or about 11% -- needed treatment in an ER or hospital room compared to nearly 16% of those given placebos. It was a 5% decrease in absolute risk and a 32% decrease in relative risk.
More study is needed to see if the drug might be added to the treatments given to coronavirus patients, but it's cheap. "A 10-day course of fluvoxamine costs approximately $4 even in well-resourced settings," the researchers wrote.
It's not a cure, but if the drug can help keep patients out of the hospital, it would be useful.
"Given fluvoxamine's safety, tolerability, ease of use, low cost, and widespread availability, these findings might influence national and international guidelines on the clinical management of COVID-19," they concluded.
A related drug, Prozac, or fluoxetine, is also cheap and even more widely available, and the researchers said this drug should be studied to see if it might help.
"It is now crucial to establish whether a class effect exists and whether these drugs can be used interchangeably for COVID-19," they wrote.
It wasn't a perfect study, they noted. It was done in Brazil, and the patients had a higher rate of hospitalization than Covid-19 patients in other clinical trials.
"There is no standard of care that exists for early treatment of COVID-19 and various advocacy groups promote different interventions, including some of those evaluated in this and our previous trials. Furthermore, there is little understanding of who is at greatest risk of disease progression from this disease as some patients with numerous risk factors do recover quickly whereas some others with less established risk factors might not," they wrote.
<<<
>>> Innovation Pharmaceuticals' COVID-19 Clinical Trial Topline Results Anticipated to Be Reported the Week of November 8th
Accesswire
October 25, 2021
https://finance.yahoo.com/news/innovation-pharmaceuticals-covid-19-clinical-113000657.html
WAKEFIELD, MA / ACCESSWIRE / October 25, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced the Company anticipates reporting topline results the week of November 8th from its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). The study data is presently blinded at the data management vendor, with final checks and approvals in progress.
The Company is also pleased to report Brilacidin has been shipped to two academic laboratories for planned in vitro testing of Brilacidin in over 20 acutely infectious viruses, including Ebola, Marburg, Nipah, West Nile and Zika, through a collaboration with U.S. government scientists. The goal of this testing is to further inform the spectrum of Brilacidin's antiviral properties.
About Brilacidin and COVID-19
Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19. Innovation Pharmaceuticals is developing Brilacidin for the treatment of COVID-19 under U.S. FDA Fast Track designation. A dual-acting inhibitor able to target viral proteins and host factors, while also exhibiting robust anti-inflammatory and antibacterial properties, Brilacidin has shown potent and consistent inhibition in vitro against coronaviruses, alphaviruses and bunyaviruses (with lab testing against other viruses also underway), supporting Brilacidin's development as a broad-spectrum antiviral. The annual global antiviral drug market is estimated to reach $44 billion by 2026.
A peer-reviewed article in Viruses supporting Brilacidin's COVID-19 treatment potential can be accessed at the link below.
Bakovic, A.; Risner, K.; Bhalla, N. (et al). Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. Viruses 2021, 13, 271; https://doi.org/10.3390/v13020271
https://www.mdpi.com/1999-4915/13/2/271/htm
Two independent Machine Learning studies identified Brilacidin as one of the most promising inhibitors of SARS-CoV-2, the virus responsible for COVID-19, based on Brilacidin's molecular properties. Click here to learn more.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases.
<<<
Maxim Group initiates coverage of KZIA with a "buy" & $18 PT, 12 month
Here is the Edison report on KZIA.
https://www.edisongroup.com/publication/multiple-paxalisib-data-points-expected-in-q4/30051
Bladerunner
re: CRIS
Raymond James initiates coverage with $15 price target.
Bladerunner
Part 2 of the discussion between Dr. Malone, Bret Weinstein, and Steve Kirsch, and they show the bioaccumulation graph for the Covid vaccine. Check out the accumulation in the ovaries (yikes) -
Background on Ridgeback Bio - >>> Hedge fund manager stands to profit on ‘flip’ of taxpayer-funded coronavirus drug
The Washington Post
By Christopher Rowland
June 25, 2020
https://www.washingtonpost.com/business/2020/06/11/coronavirus-drug-ridgeback-biotherapeutics/
Emory University’s coronavirus pill EIDD-2801 highlights financial speculation on drugs developed with public investment
Rick Bright, former director of the Biomedical Advanced Research and Development Authority, at a House Energy and Commerce subcommittee hearing on May 14. (Greg Nash/The Hill/Bloomberg News)
Clarifications: A previous version of this story gave inadequate prominence to the role of Wendy Holman, the chief executive of Ridgeback Biotherapeutics; it now introduces her by noting her professional status. In addition, this version places greater emphasis on the company’s prior experience developing an Ebola drug and includes mention of the experience of its employees in developing pharmaceutical products. The company, which declined to answer questions during the reporting of the story, said after publication that it will continue to be closely involved in the development of the coronavirus therapy, as the story now indicates.
Ridgeback Biotherapeutics had no laboratories, no manufacturing facility of its own and a minimal track record when it struck a deal in March with Emory University to license an experimental coronavirus pill invented by university researchers with $16 million in grants from U.S. taxpayers.
But what the tiny Miami company did have was a growing team with experience in pharmaceutical development and research and a willingness from its wealthy owners — chief executive Wendy Holman and her husband, hedge fund manager Wayne Holman — to place a bet on the treatment in the midst of the coronavirus pandemic. That wager paid off with extraordinary speed in May when, just two months after acquiring the antiviral therapy called EIDD-2801 from Emory, Ridgeback sold exclusive worldwide rights to drug giant Merck.
The rapid turnaround of rights to a publicly financed drug highlights the frenzy of financial speculation that has accompanied the spread of the coronavirus around the world. Congress and the Trump administration have authorized more than $7 billion for research and industry subsidies in a desperate hunt for therapies and vaccines.
The perception that companies are profiteering during a global medical crisis — especially in cases where inventions were funded by taxpayers — poses political dangers to the pharmaceutical industry.
Demands are increasing in Congress and around the world that drug companies set affordable prices on coronavirus treatments and vaccines and distribute them equitably. Yet the role of middlemen like Ridgeback puts pressure on companies to increase prices, by adding extra costs. It also raises questions about who is financially benefiting by securing monopoly licensing rights to publicly financed inventions.
Ridgeback, which has one other drug in development for Ebola, was a relatively obscure entity when it snapped up EIDD-2801 from Emory in a deal signed March 19. The university, without disclosing terms, said in a news release that Ridgeback “will be responsible for conducting the necessary trials to bring EIDD-2801 to licensure.”
Within days of securing Emory’s licensing deal, the company mounted a campaign to win hundreds of millions in government funding to develop the drug, according to a whistleblower complaint by Rick Bright, former director of the Biomedical Advanced Research and Development Authority, as well as emails obtained by The Washington Post. After failing to secure the government contracts, Ridgeback launched a human safety trial of the drug in the United Kingdom and transferred rights to Merck in late May.
In addition to an upfront payment of undisclosed size from Merck, Ridgeback will receive unspecified “milestone” payments and a share of net proceeds if the drug is approved, the companies said. Merck will conduct future clinical trials, apply for regulatory approvals and manufacture the drug, which has been shown in lab and animal studies to cripple the virus by interfering with viral RNA. Ridgeback said it will remain involved in developing the drug.
Specialists in drug development called Ridgeback’s turnaround unusually rapid.
“I would think that universities … would not normally transfer products to basically a house-flipper,” said Aaron S. Kesselheim, a physician at Brigham and Women’s Hospital in Boston and professor at Harvard Medical School. “I wouldn’t think they would have to engage with speculators, like it appears that Ridgeback Biotherapeutics is.”
Wayne Holman, who holds a medical degree from New York University, is a hedge-fund manager with a long track record of investing in pharmaceutical stocks. He founded his fund Ridgeback Capital Management in 2006. Wendy Holman, chief executive of Ridgeback Biotherapeutics, is a former investment manager who was named to President Trump’s advisory council on HIV/AIDS in 2019.
The Holmans live on Miami’s exclusive Star Island, where they bought two mansions for a combined $47 million in 2014 and tore one of them down. Ridgeback Capital’s headquarters is in a small office building not far away in Coconut Grove, near a private school where Wendy Holman serves on the board of trustees. Ridgeback has one other drug in development that has been supported with $25 million in government contracts, a potential Ebola treatment invented by a division of the National Institutes of Health. The couple did not respond to requests for comment.
EIDD-2801 is among hundreds of projects underway around the world to develop treatments and vaccines to combat the coronavirus amid signs that covid-19, the disease the virus causes, will become a stubborn, endemic illness that lingers in human populations for many years. If it works and is found to be safe, it likely would become a strong rival to Gilead’s remdesivir, the first antiviral to treat the coronavirus, which must be given intravenously.
“EIDD-2801 has several attributes including oral availability, broad antiviral activity versus multiple coronavirus strains, notably SARS-CoV-2, as shown in preclinical studies, and early clinical results showing that it is well-tolerated from a study conducted by Ridgeback,” Merck said in an email.
But the path to Merck’s portfolio of early-stage drugs has grabbed attention.
“Molecule-flipping is a good characterization of what it is,” said James Love, director of Knowledge Ecology International, a nonprofit watchdog group that tracks public investments and intellectual property.
Hunting through scientific papers and forging alliances with academic laboratories is often done by small firms backed by venture capitalists. Start-ups looking to profit by securing rights to new molecules and nurturing their early-stage development are an ingrained part of the ecosystem of drug development. The goal typically is to push a drug far enough through the approval pipeline — a process that often takes years — until a larger company buys the rights and completes commercialization.
With the coronavirus creating huge demand, that activity is accelerating, say specialists in drug licensing and intellectual property.
“Merck is much better positioned and funded to move the drug through development,” said Joseph A. DiMasi, director of economic analysis and research at the Tufts Center for the Study of Drug Development, which receives drug industry funding. “It is the speed with which this has happened that is extraordinary. That speed in the context of a pandemic is a good thing.”
Stock markets show hunger for a coronavirus treatment. But don’t expect a magic bullet.
The flood of government money is spurring attention to diseases that have been neglected by large drug companies. Vaccines and therapies for viruses do not hold the promise of large, lucrative drug sales because they are not taken as regular treatments for chronic conditions. Many virus outbreaks disappear on their own, making it risky for companies to spend on research. To plug the gap, U.S. government agencies support academic research, or invent and develop drugs directly in government labs.
“When it was limited to things like Ebola and SARS, you didn’t see as much as engagement by the private sectors. These were normally backwater areas in neglected disease,” said Love. “People now are rushing in and scaling up.”
Emory had secured pledges of $30 million in government contracts from science and defense agencies in the past five years to develop EIDD-2801 but tapped just more than half of the available funds, an Emory spokeswoman said. The university did not respond to questions about how it picked Ridgeback.
“Emory is proud that we invented EIDD-2801, and we appreciate the partnerships and government support that makes it possible to provide therapies that will benefit society,” Nancy Seideman, Emory’s vice president for academic communications, said in an email. “Any royalties that we receive — if anything — are channeled directly back to serving our educational and scientific mission.”
In instances where taxpayer-financed drugs make it to market via exclusive licensing deals — which typically have undisclosed terms — debates have sprouted around monopoly pricing.
Douglas Throckmorton, deputy director for regulatory programs at the Food and Drug Administration, speaks via teleconference at a Senate Finance Committee hearing on June 2. Some members of Congress are pushing for drug companies to set affordable prices on coronavirus treatments and vaccines. (Stefani Reynolds/Pool/AP)
Liberal members of Congress and consumer advocates have demanded that taxpayers’ investments be factored into government contracts for development of coronavirus treatments and vaccines, and that terms of licensing deals be disclosed to the public. But Democratic proposals to place constraints on prices for covid-19 therapies did not make it into the $3 billion in emergency subsidies for the drug industry that lawmakers approved in March.
Some companies with experimental medicines backed by public investment have been the subject of intense financial speculation. Investors have gambled that Gilead’s drug remdesivir, which has been proven to modestly improve outcomes, will produce a windfall for the company. The company’s stock has been subject to volatile swings in the past three months.
Remdesivir was developed with at least $70 million in public investment, according to advocates, and a debate has begun about costs and access before Gilead has even set a price.
Even finding a covid-19 vaccine won’t be enough to end the pandemic
Moderna is developing a leading vaccine candidate that is co-owned by the NIH. Government interest in the vaccine has not stopped a boost in the company’s stock of nearly 200 percent since the end of February.
EIDD-2801, which was invented as an influenza drug and has demonstrated effectiveness against multiple viruses in lab dishes, works similarly to Gilead’s remdesivir by interfering with viral RNA. But it has the advantage of being a pill, which means it could be taken by people in their homes, soon after symptoms appear. If the drug proves to be safe and effective, it could prevent countless hospitalizations and deaths and reduce the spread of infection.
Drugs in its class have been known to cause genetic mutations that lead to birth defects, but Merck said when it licensed the drug last week that it was “well-tolerated.” Wayne Holman has said the drug can safely be used for a short course of treatment to fight a viral infection.
As for potential pricing, “Merck and Ridgeback are committed to ensuring that any medicines we develop for SARS-CoV-2 will be accessible to patients globally,” Merck said in an email. It would not discuss specifics.
The deal between Emory and Ridgeback was inked by the university’s Drug Innovation Ventures at Emory (DRIVE), a nonprofit tech-transfer corporation led by Emory scientist George Painter, who holds patents related to the drug. Highly accomplished in both laboratories and boardrooms, Painter is the former chief executive of Chimerix, a North Carolina drug company, and a high-ranking official in antiviral research at the former Glaxo Wellcome. Painter did not respond to interview requests.
On March 20, the day after the Ridgeback licensing contract was completed, Painter and other scientists at the University of North Carolina, Vanderbilt University and Emory posted a preliminary scientific paper on the preprint website bioRxiv.org showing EIDD-2801 thwarted SARS-CoV-2 in human cells and in mice infected with other types of coronaviruses. The peer-reviewed journal Science Translational Medicine published the paper on April 6.
At Vanda Pharmaceuticals, a biotechnology firm headquartered in Washington, D.C., founder and chief executive Mihael Polymeropoulos saw the scientific results in the journal and had his company contact Emory about a potential licensing opportunity. It was too late.
“They came back and they said they had already done a deal with this company, Ridgeback,” Polymeropoulos said. “This deal must have happened in record speed.”
The chief operating officer at Emory’s DRIVE told the Daily Report, an Atlanta trade publication, that the licensing contract, which normally would take four to six months to complete, was negotiated and signed in two weeks after a “mad scramble” by university and Ridgeback lawyers rushing to respond to the coronavirus.
Ridgeback’s involvement burst into the broader public sphere in early May, when Bright, the ousted head of BARDA, filed his explosive whistleblower complaint. Bright alleged that he clashed with Robert Kadlec, the Health and Human Services assistant secretary for preparedness and response, over demands that he award BARDA contracts to well-connected companies. HHS has said it “strongly disagrees” with Bright’s allegations.
In his complaint, Bright cited attempts to secure money for EIDD-2801 — first by Painter in November 2019, and then by Wendy Holman in early April — among episodes of alleged political pressure.
Bright said he rejected requests to fund EIDD-2801 because Emory had already received pledges of $30 million from the National Institute of Allergy and Infectious Diseases and the Department of Defense to cover development of the drug, including human safety testing. Without first seeing safety results, Bright said, it did not make sense to back the drug with new infusions of federal cash.
Wendy Holman’s pleas for government money in early April — less than two weeks after Ridgeback secured rights to the drug from Emory — are contained in emails she wrote to government officials. The full emails, excerpts of which were cited in Bright’s whistleblower complaint, were previously disclosed by the journal Science and were obtained by The Post. Holman said in one email to BARDA that she had been in personal contact with Kadlec, who wanted the project to move forward.
“We need this approval to start the clinical trial for EIDD-2801 as soon as possible,” Wendy Holman wrote to a BARDA contracting official on April 7, just days before Ridgeback planned to launch its first human safety trials. “Lives are literally depending on it, Dr. Kadlec is pushing us to move fast, but we can’t without this authorization.”
“To avoid any delay in executing this clinical trial, Ridgeback must receive approval … as soon as possible” to incur expenses in anticipation of a contract, Holman wrote to a related agency within the Office of the Assistant Secretary for Preparedness and Response on April 3. “We desperately need guidance on this.”
Bright said in his complaint that Ridgeback had been seeking $100 million to further the drug’s development. In an April 13 email, a BARDA official said the proposal from Ridgeback could obligate the government to pay the company more than $300 million. The contract official objected to the outlay because Ridgeback had not followed proper application procedures.
Ridgeback went away empty-handed by the time Bright departed in late April. It started its safety trial on April 10, testing the EIDD-2801 drug against a placebo in 122 healthy volunteers in England, according to its disclosure on clinicaltrials.gov. It hired a contract research organization called Covance to conduct the study. The NIH said in an email that Ridgeback conducted the study at its own expense.
In an interview with The Post on April 15, before the controversy erupted, Wayne Holman talked up the drug and made it clear that Ridgeback would be seeking partnerships and investment from the private sector.
“Treating orally and early can change the course of this pandemic. Not only would it treat the person that is sick, but it should theoretically reduce the infectiousness of that person, and the time period they are infectious to others,” he said. “We have inbound interest from pharma companies.”
<<<
>>> About Ridgeback Biotherapeutics LP -
https://www.prnewswire.com/news-releases/breakthrough-ebola-treatment-receives-contract-from-us-government-301034559.html
Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman owned biotechnology company focused on orphan and infectious diseases. Initial funding for Ridgeback Biotherapeutics originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions. Ridgeback is in the process of completing a Biologics Licensing Application with the Food & Drug Administration for mAb114 (ansuvimab) for the treatment of Ebola. Ansuvimab development has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Numbers 75A50119C00059 and 75A50120C0009. Ridgeback has partnered with Emory's DRIVE group and is developing EIDD-2801, an investigational oral therapeutic for COVID-19. Ridgeback expects to begin human trials for EIDD-2801 in April 2020.
<<<
More - >>> Alleged safety concern
https://en.wikipedia.org/wiki/Molnupiravir
In May 2020, Rick Bright filed a whistleblower complaint, alleging that the Trump administration ignored his early warnings about the COVID-19 pandemic, pressured him to inappropriately fast-track unproven drugs, and illegally retaliated against him by removing him from his role as head of the Biomedical Advanced Research and Development Authority (BARDA) in April 2020.[13][14]
Among these complaints, Bright objected to providing additional federal funding to Ridgeback Biotherapeutics to further develop molnupiravir into a treatment for COVID-19. He argued that although the drug had shown potential against coronaviruses including SARS-CoV-2, it had already received substantial government support.[14] Bright also wanted to see more safety data for molnupiravir before final sign-off, due to the fact that some other nucleoside analogue drugs had caused birth defects in animal studies.[14][15]
<<<
>>> "Molnupiravir's active metabolite EIDD-1931 has been found to produce DNA mutations as well in a mammalian cell culture assay, raising concerns for potential carcinogenic and teratogenic effects" <<< -
>>> Molnupiravir
..exerts its antiviral action through introduction of copying errors during viral RNA replication
https://en.wikipedia.org/wiki/Molnupiravir
Mechanism of action
Molnupiravir is metabolized into a ribonucleoside analog that resembles cytidine, ß-D-N 4-Hydroxycytidine 5'-triphosphate (also called EIDD-1931 5'-triphosphate).[4][5][6] During replication, the virus's RNA polymerase enzyme incorporates EIDD-1931 5'-triphosphate into newly made RNA instead of using real cytidine.[6]
Molnupiravir metabolism.svg
Molnupiravir can swap between two forms (tautomers), one of which mimics cytidine (C) and the other of which mimics uridine (U).[7] When the viral RNA polymerase attempts to copy RNA containing molnupiravir, it sometimes interprets it as C and sometimes as U.[7] This causes a massive number of mutations in all downstream viral copies that exceeds the threshold the virus can survive, an effect called viral error catastrophe or lethal mutagenesis.[8]
Top, a G.C base pair with three hydrogen bonds. Bottom, an A.U base pair with two hydrogen bonds. Molnupiravir can mimic both C and U.[8] The wiggly lines stand for the connection to the pentose sugar and point in the direction of the minor groove.
Molnupiravir's active metabolite EIDD-1931 has been found to produce DNA mutations as well in a mammalian cell culture assay, raising concerns for potential carcinogenic and teratogenic effects.[9]
<<<
>>> Merck Seeks Emergency Use Authorization for Covid-19 Pill
Bloomberg
By Jason Gale and Riley Griffin
October 11, 2021
https://www.bloomberg.com/news/articles/2021-10-11/merck-seeks-emergency-use-authorization-for-pill-to-treat-covid
If cleared, molnupiravir may be first oral antiviral for Covid
Study found pill reduced hospitalization risk by about 50%
Merck & Co. and its partner Ridgeback Biotherapeutics LP sought emergency use authorization in the U.S. for molnupiravir, moving the pill closer to becoming the first oral antiviral treatment for Covid-19.
An application was submitted with the Food and Drug Administration for molnupiravir to treat mild-to-moderate Covid-19 in adults at risk of developing a severe illness that may require hospitalization, the companies said in a statement Monday. Submissions to regulatory authorities worldwide are expected in the coming months after an interim analysis of clinical trial data found it cut the risk of hospitalization for such patients by half.
Merck shares were little changed at 10 a.m. in New York on Monday.
“The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data,” said Merck Chief Executive Officer Robert M. Davis, who took the helm from Kenneth Frazier in July.
Molnupiravir can be given to patients at home, unlike Gilead Sciences Inc.’s antiviral remdesivir and monoclonal antibody therapies that are administered via intravenous infusion usually in hospitals or clinics. Treating Covid patients at home averts the risk they’ll transmit the virus to medical staff and other patients.
A five-day course of molnupiravir will cost about $700 per patient -- a third of the amount of a monoclonal antibody treatment, according to the New York Times.
Nicholas Kartsonis, senior vice-president of clinical research for infectious diseases and vaccines at Merck Research Labs, said he’s encouraged by the safety profile of the pill. “We don’t see a lot of specific adverse experiences of concern,” he said, noting Merck has shared robust data on side effects with regulators.
Asked if Merck anticipated an authorization before a potential holiday surge in infections, Kartsonis said he hopes to see clearance by Halloween.
Safe, well-tolerated, affordable and easy-to-administer antivirals are ideal treatments because they directly counter the virus, limiting its damage to the body and the duration of illness. Steroids and blood-thinners that have been shown to improve survival in hospitalized patients don’t directly fight the virus; rather they prevent a worsening of Covid symptoms.
Read More:
Merck’s Covid Pill Is Front-Runner in Elusive Antiviral Quest
Why a New Pill to Treat Covid Could Be a Game Changer
Merck’s Covid Pill Faces Risk That Virus Could Outsmart It
Merck reiterated that it expects to make 10 million treatment courses, or 400 million capsules, by the end of 2021. “Substantially more will be produced in 2022,” said Paul Schaper, Merck’s executive director of global pharmaceutical public policy, in an interview.
The Kenilworth, New Jersey-based drugmaker agreed in June to a $1.2 billion supply deal to provide the U.S. government 1.7 million courses of treatment once the drug gains FDA authorization or approval. Looking globally, Schaper said he anticipates “a number of other announcements being made over the course of the next several weeks.”
Merck will continue to aim to make voluntary licenses available to third-party generic drug manufacturers so that the pill can be produced at scale for low and middle-income countries, Schaper said.
<<<
>>> Vaccine Stocks Shed $84 Billion as Merck Pill Adds to Rough Week
Bloomberg
By Bailey Lipschultz
October 1, 2021
https://www.bloomberg.com/news/articles/2021-10-01/vaccine-stocks-shed-84-billion-as-merck-pill-adds-to-rough-week?srnd=premium
Merck’s entry ‘has to dampen the day’ for Covid-19 stocks
Share losses hit companies beyond those selling vaccines
Merck Says Covid Pill Cut Hospitalizations, Deaths by Half
For the world’s leading Covid-19 vaccine makers, news that Merck & Co.’s experimental pill cuts the risk of hospitalization and death in half was the latest blow in a very bad week.
Stocks including Moderna Inc. and BioNTech SE have shed about $84 billion in combined value this week in the aftermath of a stock market slump that sent the two companies to their lowest level since July.
Selling accelerated on Friday, with BioNTech and Moderna each declining as much as 16% in New York as Merck delivered the news on its experimental pill that Wall Street called a “game changer.” The drug, called molnupiravir, reduced the risk of hospitalization or death by 50% in a study, raising concerns about the long-term revenues for companies providing inoculations.
Vaccine stocks stumble amid market selloff, Merck pill data
“You have news of a new player coming into the market with a much less rigorous treatment and that alone has to dampen the day for the rest of the field whether they’re vaccines or drugs administered in the hospital for Covid-19,” said Jared Holz, managing director of healthcare equities at Oppenheimer & Co. “The vaccine revenue numbers over the next few years would have to come down.”
Wall Street analysts had forecast Moderna’s Covid-19 vaccines will bring in more than $20 billion in sales this year, before dropping to $6.1 billion by 2025.
Not Over Yet
In spite of this week’s selloff, vaccine stocks remain among biotech’s top performers since the start of the pandemic. Moderna shares are up 1,590% since the start of 2020, while BioNTech and peer Novavax Inc. have seen similarly eye-popping gains of 600% and 4,000%, respectively.
Not all investors see Merck’s Covid-19 breakthrough as a reason to shun all vaccine makers. The pandemic is far from over, argues Brad Loncar, chief executive officer of Loncar Investments.
“Time and time again we’ve seen that a quick take to positive news thinking that this means the pandemic is over has been wrong every single time,” he said by phone. “I don’t think this is going to hurt the vaccine companies as much as maybe a quick reaction would infer.”
Read more: Atea Pharma Soars 33% as Merck Covid Pill Data is ‘Encouraging’
Selling spread beyond vaccine stocks and biotechnology companies.
Companies that have developed or are working on antibody treatments for Covid-19 and closely-watched exchange-traded funds like the iShares Biotechnology ETF, also fell.
Here’s how some of them performed on Friday:
BioNTech and Moderna each crashed as much as 16% to the lowest since July
Novavax tumbled as much as 26% while vaccine peers sank: CureVac -16%,
Arcturus Therapeutics -10%, Inovio Pharmaceuticals Inc. -8.9%
Companies with antibody treatments for Covid: Adagio Therapeutics Inc.
-42%, Vir Biotechnology Inc. -24%, AbCellera Biologics Inc. -14%, Regeneron Pharmaceuticals Inc. -8.1%
iShares Biotechnology ETF falls as much as 4.1%, the most since late March
The broader health-care sector fell four the fifth time in the past six sessions Friday, with life sciences toolmakers and medical device companies underperforming the broader market. The S&P 500 Health Care Index’s 5% drop this week is the group’s worst week since October 2020.
<<<
>>> A pill to treat Covid-19: 'We're talking about a return to, maybe, normal life'
Oct 1, 2021
CNN
By JoNel Aleccia, Kaiser Health News
https://www.msn.com/en-us/health/medical/a-pill-to-treat-covid-19-were-talking-about-a-return-to-maybe-normal-life/ar-AAOSro2?li=BBnb7Kz
Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.
When her husband, Joe, 46, fell ill with the virus, too, she really got worried, especially about their five teenagers at home: "I thought, 'I hope to God we don't wind up on ventilators. We have children. Who's going to raise these kids?"
But the Kellys, who live in Seattle, had agreed just after their diagnoses to join a clinical trial at the nearby Fred Hutch cancer research center that's part of an international effort to test an antiviral treatment that could halt covid early in its course.
By the next day, the couple were taking four pills, twice a day. Though they weren't told whether they had received an active medication or placebo, within a week, they said, their symptoms were better. Within two weeks, they had recovered.
"I don't know if we got the treatment, but I kind of feel like we did," Miranda Kelly said. "To have all these underlying conditions, I felt like the recovery was very quick."
The Kellys have a role in developing what could be the world's next chance to thwart covid: a short-term regimen of daily pills that can fight the virus early after diagnosis and conceivably prevent symptoms from developing after exposure.
"Oral antivirals have the potential to not only curtail the duration of one's covid-19 syndrome, but also have the potential to limit transmission to people in your household if you are sick," said Timothy Sheahan, a virologist at the University of North Carolina-Chapel Hill who has helped pioneer these therapies.
Antivirals are already essential treatments for other viral infections, including hepatitis C and HIV. One of the best known is Tamiflu, the widely prescribed pill that can shorten the duration of influenza and reduce the risk of hospitalization if given quickly.
The medications, developed to treat and prevent viral infections in people and animals, work differently depending on the type. But they can be engineered to boost the immune system to fight infection, block receptors so viruses can't enter healthy cells, or lower the amount of active virus in the body.
At least three promising antivirals for covid are being tested in clinical trials, with results expected as soon as late fall or winter, said Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, who is overseeing antiviral development.
"I think that we will have answers as to what these pills are capable of within the next several months," Dieffenbach said.
The top contender is a medication from Merck & Co. and Ridgeback Biotherapeutics called molnupiravir, Dieffenbach said. This is the product being tested in the Kellys' Seattle trial. Two others include a candidate from Pfizer, known as PF-07321332, and AT-527, an antiviral produced by Roche and Atea Pharmaceuticals.
They work by interfering with the virus's ability to replicate in human cells. In the case of molnupiravir, the enzyme that copies the viral genetic material is forced to make so many mistakes that the virus can't reproduce. That, in turn, reduces the patient's viral load, shortening infection time and preventing the kind of dangerous immune response that can cause serious illness or death.
So far, only one antiviral drug, remdesivir, has been approved to treat covid. But it is given intravenously to patients ill enough to be hospitalized, and is not intended for early, widespread use. By contrast, the top contenders under study can be packaged as pills.
Sheahan, who also performed preclinical work on remdesivir, led an early study in mice that showed that molnupiravir could prevent early disease caused by SARS-CoV-2, the virus that causes covid. The formula was discovered at Emory University and later acquired by Ridgeback and Merck.
Clinical trials have followed, including an early trial of 202 participants last spring that showed that molnupiravir rapidly reduced the levels of infectious virus. Merck chief executive Robert Davis said this month that the company expects data from its larger phase 3 trials in the coming weeks, with the potential to seek emergency use authorization from the Food and Drug Administration "before year-end."
Pfizer launched a combined phase 2 and 3 trial of its product Sept. 1, and Atea officials said they expect results from phase 2 and phase 3 trials later this year.
If the results are positive and emergency use is granted for any product, Dieffenbach said, "distribution could begin quickly."
That would mean millions of Americans soon could have access to a daily orally administered medication, ideally a single pill, that could be taken for five to 10 days at the first confirmation of covid infection.
"When we get there, that's the idea," said Dr. Daniel Griffin, an infectious diseases and immunology expert at Columbia University. "To have this all around the country, so that people get it the same day they get diagnosed."
Once sidelined for lack of interest, oral antivirals to treat coronavirus infections are now a subject of fierce competition and funding. In June, the Biden administration announced it had agreed to obtain about 1.7 million treatment courses of Merck's molnupiravir, at a cost of $1.2 billion, if the product receives emergency authorization or full approval. The same month, the administration said it would invest $3.2 billion in the Antiviral Program for Pandemics, which aims to develop antivirals for the covid crisis and beyond, Dieffenbach said.
The pandemic kick-started a long-neglected effort to develop potent antiviral treatments for coronaviruses, said Sheahan. Though the original SARS virus in 2003 gave scientists a scare — followed by Middle East respiratory syndrome, or MERS, in 2012 — research efforts slowed when those outbreaks did not persist.
"The commercial drive to develop any products just went down the tubes," said Sheahan.
Widely available antiviral drugs would join the monoclonal antibody therapies already used to treat and prevent serious illness and hospitalizations caused by covid. The lab-produced monoclonal antibodies, which mimic the body's natural response to infection, were easier to develop but must be given primarily through intravenous infusions.
The federal government is covering the cost of most monoclonal products at $2,000 a dose. It's still too early to know how the price of antivirals might compare.
Like the monoclonal antibodies, antiviral pills would be no substitute for vaccination, said Griffin. They would be another tool to fight covid. "It's nice to have another option," he said.
One challenge in developing antiviral drugs quickly has been recruiting enough participants for the clinical trials, each of which needs to enroll many hundreds of people, said Dr. Elizabeth Duke, a Fred Hutch research associate overseeing its molnupiravir trial.
Participants must be unvaccinated and enrolled in the trial within five days of a positive covid test. Any given day, interns make 100 calls to newly covid-positive people in the Seattle area — and most say no.
"Just generally speaking, there's a lot of mistrust about the scientific process," Duke said. "And some of the people are saying kind of nasty things to the interns."
If the antiviral pills prove effective, the next challenge will be ramping up a distribution system that can rush them to people as soon as they test positive. Griffin said it will take something akin to the program set up last year by UnitedHealthcare, which sped Tamiflu kits to 200,000 at-risk patients enrolled in the insurer's Medicare Advantage plans.
Merck officials predicted the company could produce more than 10 million courses of therapy by the end of the year. Atea and Pfizer have not released similar estimates.
Even more promising? Studies evaluating whether antivirals can prevent infection after exposure.
"Think about that," said Duke, who is also overseeing a prophylactic trial. "You could give it to everyone in a household, or everyone in a school. Then we're talking about a return to, maybe, normal life."
<<<
Cardiff Oncology - >>> James Levine Is The Chief Financial Officer of Cardiff Oncology, Inc. (NASDAQ:CRDF) And Just Spent US$194k On Shares
Simply Wall St
September 15, 2021
https://finance.yahoo.com/news/james-levine-chief-financial-officer-103747648.html
Potential Cardiff Oncology, Inc. (NASDAQ:CRDF) shareholders may wish to note that the Chief Financial Officer, James Levine, recently bought US$194k worth of stock, paying US$6.47 for each share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.
See our latest analysis for Cardiff Oncology
Cardiff Oncology Insider Transactions Over The Last Year
In fact, the recent purchase by James Levine was the biggest purchase of Cardiff Oncology shares made by an insider individual in the last twelve months, according to our records. That means that even when the share price was higher than US$6.51 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
In the last twelve months Cardiff Oncology insiders were buying shares, but not selling. Their average price was about US$8.28. This is nice to see since it implies that insiders might see value around current prices. The chart below shows insider transactions (by companies and individuals) over the last year.
Does Cardiff Oncology Boast High Insider Ownership?
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests Cardiff Oncology insiders own 1.7% of the company, worth about US$4.4m. We prefer to see high levels of insider ownership.
What Might The Insider Transactions At Cardiff Oncology Tell Us?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Cardiff Oncology insiders are expecting a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 5 warning signs for Cardiff Oncology (of which 3 are a bit concerning!) you should know about.
<<<
>>> Dynavax: In Line for a Big Revenue Stream From Covid-19 Vaccine’s Potential Approval
TipRanks
September 27, 2021
https://finance.yahoo.com/news/dynavax-line-big-revenue-stream-153948438.html
There’s a potential new addition to the lineup of successful Covid-19 vaccines. In fact, Cowen's Phil Nadeau thinks Clover and Dynavax’ (DVAX) collaborative effort SCB-2019 appears “better tolerated than approved COVID vaccines.”
Nadeau’s exuberant take follows Clover’s last Wednesday's announcement. The company disclosed that its Covid-19 vaccine SCB-2019 – which makes use of Dynavax’ adjuvant technology – showed excellent results in a Phase 3 study.
The vaccine produced 100% protection against severe disease/hospitalization, 84% against moderate-to-severe disease, and a 79% protection rate against the Delta variant. Overall, the vaccine demonstrated a 67% efficacy rate against all COVID infections of any severity.
While the overall rate might appear low, the already approved vaccines from Moderna and Pfizer went through the testing process before today's variants of concern had become widespread, and therefore Nadeau believes the results “are all the more meaningful in the context of 100% prevalence of COVID-19 variants in the study population.”
“We think these data are sufficiently strong to support approvals in global markets, and allow Clover to capture share,” the 5-star analyst went on to say.
Not to mention, Dynavax stands to rake in a meaningful revenue stream from SCB-2019’s commercialization. In June, Clover said it had reached an advanced purchase agreement with Gavi, the Vaccine Alliance. Through 2022, Clover will supply 414 million doses of SCB-2019 which will go toward the COVAX Facility - the initiative to expand worldwide vaccine access. Moreover, the company estimates it has the ability to manufacture over 1 billion doses a year. Given Clover's “potential scale and DVAX's anticipated economics (10-25%),” the revenue windfall from SCB-2019’s commercialization could be a big deal for Dynavax.
In Q4, Clover intends on filing for conditional approval to several global regulatory bodies including China NMPA, EMA and WHO, with a commercial launch possibly coming before the end of 2021, pending conditional approval.
Based on the above, Nadeau stays with the bulls, reiterating an Outperform (i.e. Buy) rating along with a $20 price target. (To watch Nadeau’s track record, click here)
Three other analysts have thrown the hat in recently with DVAX reviews, and all are of the same mind – Buy. The stock’s Strong Buy consensus rating is backed by a $20.67 average price target, suggesting room for a 7% uptick over the coming months. (See Dynavax stock analysis on TipRanks)
<<<
Name | Symbol | % Assets |
---|---|---|
Regeneron Pharmaceuticals Inc | REGN | 2.77% |
Moderna Inc | MRNA | 2.65% |
Gilead Sciences Inc | GILD | 2.43% |
Vertex Pharmaceuticals Inc | VRTX | 2.32% |
Biogen Inc | BIIB | 2.28% |
United Therapeutics Corp | UTHR | 2.26% |
Biomarin Pharmaceutical Inc | BMRN | 2.25% |
Seattle Genetics Inc | SGEN | 2.16% |
Exelixis Inc | EXEL | 2.06% |
ACADIA Pharmaceuticals Inc | ACAD | 2.04% |
Name | Symbol | % Assets |
---|---|---|
Regeneron Pharmaceuticals Inc | REGN | 4.88% |
Gilead Sciences Inc | GILD | 4.58% |
Qiagen NV | QGEN | 4.48% |
Biogen Inc | BIIB | 4.28% |
Seattle Genetics Inc | SGEN | 4.08% |
United Therapeutics Corp | UTHR | 3.93% |
Vertex Pharmaceuticals Inc | VRTX | 3.89% |
ACADIA Pharmaceuticals Inc | ACAD | 3.75% |
Biomarin Pharmaceutical Inc | BMRN | 3.69% |
Alnylam Pharmaceuticals Inc | ALNY | 3.53% |
Name | Symbol | % Assets |
---|---|---|
Pacific Biosciences of California Inc | PACB | 6.85% |
Teladoc Health Inc | TDOC | 5.94% |
CRISPR Therapeutics AG | CRSP | 5.77% |
Twist Bioscience Corp | TWST | 5.72% |
CareDx Inc | CDNA | 3.87% |
Iovance Biotherapeutics Inc | IOVA | 3.59% |
Exact Sciences Corp | EXAS | 3.58% |
Fate Therapeutics Inc | FATE | 3.47% |
Invitae Corp | NVTA | 3.42% |
Personalis Inc | PSNL | 3.26% |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |